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1. Introduction 
 
Angiotensin I converting enzyme (ACE) is a zinc peptidyl dipeptidase that catalyses the 
conversion of angiotensin I to angiotensin II, which is a potent vasoconstrictor and is also 
involved in the inactivation of bradykinin, a potent vasodilator (1). ACE plays an important 
role in blood pressure regulation by virtue of generating angiotensin II, which increases blood 
pressure by inducing aldosterone secretion, leading to sodium and fluid retention and the 
release of norepinephrine from the sympathetic nervous system (2). Apart from regulating 
blood pressure, angiotensin II, an important effector of the renin-angiotensin system (RAS), is 
a potent proinflammatory agent leading to expression of growth factors, cytokines, 
chemokines and adhesion molecules, in pathological conditions wherein RAS is activated (3-
6). Increased local ACE activity leading to increased de novo production of angiotensin II 
coupled with degradation of bradykinin, impairs the balance between vasoconstriction and 
vasodilation, thrombogenesis and fibrinolysis, proinflammation and anti-inflammation thus 
promoting pathological effects in hypertension (7). ACE inhibitors are widely employed for 
the treatment of hypertension and various cardiovascular diseases (8). The observed beneficial 
cardiac, vascular and renal effects cannot be explained by the blood pressure lowering action 
of ACE inhibitors alone, and also the magnitude of risk reduction was far greater than that 
expected from the modest reduction in blood pressure. Therefore the study of ACE and 
mechanisms of ACE inhibitors is needed to fully explain the beneficial effects of ACE 
inhibitors. To explain the mode of action of ACE inhibitors, our group recently identified 
ACE as a signal transduction molecule because upon binding of ACE inhibitors, an outside-in 
signalling is initiated leading to a signalling cascade resulting in the phosphorylation of 
Ser
1270 in the cytoplasmic tail of ACE, activation of JNK as well as the phosphorylation of c-
Jun and its translocation to the nucleus affecting the increased expression of ACE and 
cyclooxygenase-2 (COX-2) in endothelial cells. This ACE inhibitor induced signalling 
cascade could potentially influence the expression of a spectrum of genes in endothelial cells 
and this could be an additional mechanism by which ACE inhibitors exert their protective 
effects on the cardiovascular system. This thesis describes the mechanism by which the ACE 
inhibitor initiates the signalling cascade and attempts to identify the downstream effectors of 
the ACE signalling cascade. 
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1.1. The Renin Angiotensin System 
 
The RAS plays an important role in regulating blood volume, arterial pressure, cardiac and 
vascular function. Sympathetic stimulation (acting via β1-adrenoceptors), renal artery 
hypotension, and decreased sodium delivery to the distal tubules stimulate the release of renin 
by the kidney. Renin is an enzyme that acts upon a circulating substrate, liver-derived 
angiotensinogen that undergoes proteolytic cleavage and forms the decapeptide angiotensin I. 
Angiotensin I, per se has only weak physiological activity and mainly acts as a precursor to 
angiotensin II. In addition to being a substrate for angiotensin II, angiotensin I can be 
converted to heptapeptide angiotensin 1-7 by neutral endopeptidase and also by the recently 
discovered angiotensin converting enzyme 2 (ACE2). ACE2 can also remove a single amino 
acid from the carboxyl terminus of angiotensin I to produce angiotensin 1-9 (Fig. 1). 
ACE, located in the vascular endothelium, particularly in the lungs, cleaves two amino acids 
from the C-terminus to form the octapeptide, angiotensin II. Alternatively, angiotensin II can 
be converted to angiotensin 1-7 by ACE2. Angiotensin II can be converted to smaller peptides 
with biological activity by the action of aminopeptidase A, which removes a single amino 
acid from the amino terminus to generate angiotensin III or angiotensin 2-8. Additional action 
of aminopeptidases can generate angiotensin IV or angiotensin 3-8. Angiotensin III has 40% 
of the pressor activity of angiotensin II, but 100% of the aldosterone-producing activity. 
Angiotensin 1-7 has been reported to have vasodilatory effects (9). 
 
Fig 1. The components of the renin angiotensin system and the kinin kallikrein system.  
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Angiotensin II mediates its effects via binding to specific receptors on the cell surface. At 
least two types of angiotensin receptors which are G-protein coupled have been identified: 
angiotensin II type 1 (AT1) and type 2 (AT2) receptors. Most of the effects of angiotensin II 
are mediated via AT1 receptors to stimulate systemic vasoconstriction, vascular smooth 
muscle contraction, aldosterone secretion, dipsogenic responses, pressor and tachycardiac 
responses.  
Angiotensin II acting via AT1 receptors, can also cause cell growth, differentiation and 
proliferation directly by affecting several kinase pathways and indirectly by inducing several 
growth factors, including transforming growth factor β1 (TGF-β1) and platelet-derived growth 
factor (PDGF) (10).  The AT2 receptor is highly expressed in fetal mesenchymal tissues from 
both rodents and man and diminishes rapidly to low levels a few days after birth. However 
AT2 receptor protein is detectable in the adult kidney, heart and blood vessels. The  expression 
of the AT2  receptor is upregulated by sodium depletion and is inhibited by angiotensin II and 
growth factors such as platelet-derived growth factor, epidermal growth factor and also by 
insulin and insulin growth factor-I (11-13). Growing evidence shows that AT2 receptors are 
also important in controlling the cardiovascular system (10). A physiological role for the AT2  
receptor was first suggested by the observations that mice lacking the AT2 receptor have a 
slight but significant increase in baseline blood pressure (11;14). The AT2  receptor 
subsequently mediates vasodilation by stimulating the production of bradykinin, nitric oxide 
(NO) and cyclic guanosine 3’, 5’-monophosphate (cGMP) (15;16). In blood vessels, in 
addition to its vasodilatory actions, the AT2 receptor exerts antiproliferative and apoptotic 
effects in vascular smooth muscle cells and decreases neointimal formation in response to 
injury by counteracting the effects of angiotensin II (17). It seems that most of the effects 
mediated by AT2 receptors are the opposite of those mediated by AT1 and it is also suggested 
that the AT2  receptor exerts protective actions only when the AT1 receptor is blocked (18;19).  
Apart from angiotensin II, angiotensin III also can bind to and signal through the AT1 and 
AT2 receptors.  
The components of the RAS have been found in a number of tissues, which partly explains 
the increased concentration of circulating angiotensin II levels during long term ACE 
inhibitor therapy. Other peptidases are able to convert angiotensin I to angiotensin II and the 
serine protease chymase are thought to be responsible for more than 80% of the angiotensin II 
formation in the human heart and more than 60% of that in the arteries (20;21). However the  
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role of RAS in other tissues warrants further investigation. The physiological role of RAS is 
to maintain or increase extracellular fluid volume and to increase the total peripheral 
resistance. An effective RAS attenuates orthostatic hypotension and hypotension during low  
salt intake or during dehydration. Overactivity of RAS has been implicated in the 
development of various cardiovascular diseases, such as hypertension, congestive heart 
failure, coronary ischemia, atherosclerosis and renal insufficiency (22). 
 
1.2. ACE inhibitors 
 
ACE inhibitors are a preferred class of drugs used clinically to treat high blood pressure. ACE 
inhibitors are most effective in lowering blood pressure in experimental models of 
hypertension such as in genetically hypertensive rats (spontaneously hypertensive rats) and 
mice (23-25). Findings from large clinical trials have established that blocking the renin-
angiotensin system with ACE inhibitors not only lower blood pressure but also positively 
influence a number of cardiovascular risk factors such as cardiac and vascular hypertrophy, 
endothelial dysfunction, atherosclerosis or insulin resistance.  
ACE inhibitors are tight-binding competitive inhibitors of ACE. They interact with the 
constituents of the enzyme’s active site, i.e. the hydrophobic pocket, positively charged 
groups of amino acids, the zinc
 ion and auxiliary binding sites. Captopril, the first clinically 
available ACE inhibitor, belongs to the group of sulfhydryl (SH)- containing ACE inhibitors 
(26). Based on the structure of captopril, other inhibitors were synthesized such as enalaprilat, 
lisinoprilat (27), ramiprilat (28;29) and perindoprilat (30). More than 15 inhibitors of the 
enzyme are now clinically available worldwide. ACE inhibitors can be divided into three 
chemical classes according to their zinc ligand (31;32). They mainly differ in their elimination 
half-life, potency, lipophilicity and the route of elimination.  
ACE inhibitors significantly improved endothelial function by increasing the formation of NO 
and prostaglandin PGI2 (33-36), vascular remodelling (37) inhibited the progression of 
arteriosclerosis (38) and delayed the onset of type-2 diabetes (39;40). ACE inhibitors results 
in significant reductions in mortality in heart failure and post-myocardial infarct patients (41). 
The effects of ACE inhibition in patients with high risk for coronary artery disease without 
left ventricular dysfunction or heart failure, patients at least 55 years old with a history of 
stroke, peripheral vascular disease and diabetic patients were examined in the heart outcomes 
prevention evaluation (HOPE) study. Treatment with ramipril significantly reduced the 
combined outcome of death, myocardial infarction and stroke by 22% and revascularizations  
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by 16%. In diabetic patients, ramipril lowered the risk of new onset of diabetes by 32%, 
diabetic complications by 16%. ACE inhibitors have been shown to decrease the clinical 
events in high risk patients with atherosclerosis with and without ventricular dysfunction, 
prior to and after myocardial infarction (42-44). The positive effects of ACE inhibitors 
observed in HOPE and other studies of ACE inhibition, cannot be explained by the blood 
pressure lowering action of ACE inhibitors alone, since the magnitude of risk reduction was 
greater than that expected from the modest reductions in blood pressure that occurred (45). 
Therefore the study of mechanism of action of ACE inhibitors apart from lowering blood 
pressure or independent of angiotensin II or bradykinin, is needed to explain the positive 
beneficial effects demonstrated by various large clinical trials.  
 
1.3. The Angiotensin Converting Enzyme 
 
Cells and tissues not implicated in the classical RAS are now known to possess the 
components of RAS and exert diverse actions in many organs. ACE is found in most 
mammalian tissues bound to the external surface of the plasma membrane of vascular 
endothelial cells. ACE is also present in epithelial, neural and neuroepithelial cell types (46). 
ACE is located in the parenchyma of the heart, kidneys, brain, and adrenal glands. Apart from 
the vasculature, ACE is also found in circulating leukocytes and monocytes. T lymphocytes 
have higher enzyme protein levels than monocytes (47). Various components of the renin-
angiotensin system
  have been localized to human adipose tissue (48;49). Taken together, 
emerging picture of ACE expression in many other tissues suggests that the enzyme might 
play other roles apart from conversion of angiotensin I to angiotensin II, which needs further 
investigation. The structural aspects of the enzyme, isoforms and homologues of ACE, 
polymorphisms of ACE, ACE in other tissues apart from vasculature, wherein it might play a 
new role and its role as a signal transduction molecule, all of which will be discussed in the 
sections to follow.  
 
1.3.1. Structure 
 
ACE exists as a cell surface integral membrane glycoprotein (class I membrane protein) 
anchored to the plasma membrane with the N-terminus and active site facing the extra-cellular 
milieu, in particular at the luminal surface of vascular endothelial cells (Fig. 2) (50). ACE 
consists of a 28 residue carboxyl-terminal cytosolic domain and a 22 residue hydrophobic 
transmembrane domain and an extracellular domain consisting of 1227 residues.  
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The extracellular domain is further divided into two homologous domains, a 612 residue N- 
domain at the amino terminus linked by a 15 residue sequence to a 600 residue C domain. 
Each of the extracellular domains possess an active site with a HEXXH sequence in which the 
two histidine residues serve as zinc-binding ligands (51). 
 
Fig. 2: Schematic representation showing the structure of angiotensin converting enzyme 
(ACE). Catalytic sites on each lobe binds a zinc (Zn
2+) atom. Modified from Johnston et al 
(52). 
 
ACE is a metallopeptidase with a zinc atom in its active center, its activity can therefore be 
inhibited by metal chelating agents. Despite their high degree of homogeneity, the N and C 
domains display distinct structural and functional differences. The C domain is primarily 
responsible for angiotensin I hydrolysis, while both N and C domains are responsible for the 
inactivation of bradykinin (53-55). The N domain preferentially hydrolyses the 
haemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro (AcSDKP) and angiotensin 1-7 (56). The 
C domain displays greater chloride dependence (55;57) and is more sensitive to proteolysis 
(58), while the N domain shows greater thermal stability (59). In addition, ACE inactivates 
the vasodilatory peptide brakykinin by the sequential removal of two C-terminal dipeptides 
(60). However bradykinin is the preferred substrate of both catalytic sites, as ACE hydrolyzes 
bradykinin 80 times faster than angiotensin I (61;62). Therefore, the net physiological effect 
of ACE is to increase the production of vasoconstrictor and decrease the availability of 
vasodilator. 
Carboxyl terminal 
catalytic site
Amino terminal 
catalytic site 
N NH H2 2   
C CO OO OH H
Zn
2+
Zn
2+
Extracellular 
domain 
Transmembrane 
domain 
Intracellular 
domain Introduction   9   
 
Table 1: Arrows indicate the primary sites of cleavage by human ACE. Adapted from 
Skidgel et al (63) 
 
The testicular ACE is O-glycosylated, whereas the somatic ACE is principally N-
glycosylated. The role of glycosylation is not well understood; probably it may enhance the 
solubility of the enzyme. It has also been suggested that the extent of juxtamembrane 
glycosylation within somatic ACE regulates dimerization of the protein via the involvement 
of a carbohydrate-recognizing domain and subsequent formation of intermolecular disulphide 
bridges (64). On the other hand glycosylation per se does not seem to participate in the 
catalytic properties of ACE, although it can protect, in particular the N-terminal domain, 
against proteinases such as trypsin (65-67).  
 
1.3.2. ACE isoforms        
                                                                                                                                                                               
There are two ACE isoforms: a somatic form of about 150-180 kDa, and a smaller isoform 
(90-110 kDa) found exclusively in the testes (68). The human somatic form of ACE, a 170-
kDa glycoprotein, has been shown by molecular cloning of its complementary 
deoxyribonucleic acid (cDNA) to consist of two homologous domains, each containing an 
active site (57;69). The somatic isoform of the enzyme consists of two highly homologous 
and functionally active domains, the so-called amino/N terminal and the carboxy/C terminal 
domain, resulting from gene duplication (57;70), while the testicular isoform has only one of 
these two domains (71-73).  Introduction   10   
 
1.3.3. ACE genetics 
 
The human ACE gene is composed of 26 exons, but the mature endothelial transcript is 4.3 kb 
long and composed of only 25 exons as exon 13 is spliced off in this transcript. The testicular 
ACE transcript is 3 kb long and transcribed from exons 13 to 26. Therefore a single gene 
encodes both the somatic and testicular ACE transcripts by activation of alternate promoters 
(69;72;74). There are two ACE promoters, a somatic promoter which is located on the 5’ side 
of the first exon of the gene and a germinal, promoter located on the 5’ side of the specific 
testicular ACE mRNA (74). The two alternate promoters of the ACE gene exhibit highly 
contrasting cell specificities, as the somatic promoter is active in endothelial, epithelial and 
neuronal cell types, whereas the germinal promoter is only active in a stage specific manner in 
male germinal cells (75). Expression of both the somatic and testicular ACE is under different 
hormonal regulation i.e. the endothelial enzyme is induced by glucocorticoids, whereas the 
testicular form is stimulated by androgens (76;77).  
 
1.3.4. ACE polymorphisms 
 
It is generally thought that plasma ACE concentration mirrors the level of the synthesis of the 
somatic enzyme. The cloning of human ACE gene also enabled the detection of many 
polymorphisms. One of them consists of the presence (insertion allele I) or absence (deletion 
allele D) of a 287-base pair DNA fragment in the intron 16 of the ACE gene, corresponding to 
an Alu sequence. A strong association of these alleles and the level of serum ACE was 
detected (78;79). Individuals homozygous for the D allele (genotype DD) displayed twice as 
high serum ACE levels compared to individuals homozygous for the I allele (genotype II) 
(79-82). Also, carriers of the D allele have been found to have significantly higher risk of 
diabetic nephropathy (83). 
 
1.4. ACE secretion 
 
Despite the fact that ACE is expressed as a type I integral membrane protein, a soluble form 
of ACE is found in plasma, seminal fluids and other body fluids (84). This soluble form is 
derived from the membrane-bound form through the action of ACE secretase (85;86). 
Proteolytic cleavage of membrane-bound ACE occurs at different positions within the 
juxtamembrane stalk region (87;88). Of physiological relevance, a point mutation within the 
juxtamembrane region (Pro-1199 to Leu) has been shown to cause a dramatic increase in 
serum levels of ACE (89). The same mutation has been shown to enhance ACE shedding in Introduction   11   
vitro (90). Intermolecular disulfide bridge formation and the extent of glycosylation within 
the ACE juxtamembrane region has been shown to modulate the degree of shedding of the 
enzyme (91) thereby also altering the cleavage site by secretases (92). Somatic ACE is shed 
much less efficiently than testicular ACE as the N-terminal domain of somatic ACE also 
plays an important regulatory role by occluding a recognition motif on C-domain required for 
ectodomain shedding (93).  
Increased serum ACE levels has been reported in Sarcoidosis (94), diabetes, Gaucher’s 
disease (95), leprosy and to a lesser extent in hyperthyroidism (96). Increased plasma ACE 
activity has been suggested to be a risk factor for patients with coronary artery disease and 
myocardial infarction (97;98). Elevated plasma ACE activity determined soon after the  onset 
of MI has been suggested  to be a significant predictor of development of left ventricular 
dilation (99). On the other hand, decreased soluble ACE has been reported in vascular 
pathologies involving an endothelial abnormality, for instance deep vein thrombosis (100), 
pulmonary injury (96;101) and in endothelial dysfunction related to the toxicity of chemo- 
and radiotherapy used in cancer, leukemia and hematopoietic or organ transplantation 
(96;102). Therefore soluble ACE can be of interest as a prognostic marker for monitoring 
arterial hypertension and diabetic patients treated with specific ACE inhibitors.  
 
1.5.  ACE in other tissues 
 
1.5.1 Human monocytes 
 
Both monocytes and macrophages are instrumental in maintaining the homeostasis of the 
immune system and also are involved in pathological events. Freshly isolated monocytes 
contain little or no detectable ACE activity (103). However, when cultured for 4 days and also 
when monocytes differentiate into macrophages (104), ACE levels increases substantially. 
Differentiation of monocytes into macrophages in culture is also accompanied by an increase 
in the expression of components of renin-angiotensin system (105;106). Dexamethasone also 
was able to induce ACE expression in monocytes in culture (107). The biological relevance of 
ACE induction in monocytes is not yet clear, however due to its carboxypeptidase activity, 
ACE enhances the presentation of certain endogenously synthesized peptides to MHC class I-
restricted cytotoxic T-lymphocytes, by generation of optimally sized class I-binding peptides 
from larger protein fragments (108-110). The level of ACE expression in the mononuclear 
cells that synthesize ACE is genetically determined and dependent on ACE polymorphisms in 
vivo (47). Activation of monocytes occurs in pathological conditions and it was demonstrated 
that dialysis patients with manifest cardiovascular disease had significant ACE levels in Introduction   12   
circulating monocytes thus suggesting a general activation of the renin-angiotensin system 
contributing to atherosclerosis (111). It was reported that there is an increased accumulation 
of ACE in atherosclerotic coronary artery disease (112). In the regions of plaques where 
macrophages and foam cells accumulate, there is also an elevated concentration of ACE 
which produces increased amounts of angiotensin II, which in turn is atherogenic and has 
proinflammatory properties, thereby promoting the risk of plaque rupture.  
 
1.5.2. Heart and vasculature 
 
The components of RAS have been found in the cardiomyocytes, vascular smooth muscle 
cells and endothelial cells. By means of immunohistochemistry, ACE expression has been 
localized to the cardiac blood vessels and the endocardium (113). ACE levels are increased in 
vascular and cardiac hypertrophy. Adminstration of ACE inhibitors led to efficient treatment 
of cardiac disease. Local ACE expression plays an important role in cardiac remodeling as 
reported that the in-vivo gene transfer of ACE into the uninjured rat carotid artery results in 
the development of vascular hypertrophy independent of its effect on blood pressure per se 
(114). 
 
1.5.3. Adipose tissue 
 
Local RAS components have also been detected in white and brown adipose tissue. ACE 
mRNA was found in both human subcutaneous and extraperitoneal adipose tissue, especially 
in adipocytes (115). ACE synthesis at protein levels was detected in human preadipocytes 
(116). The expression of RAS components seems to be related to body weight because obese 
women are reported to have higher circulating angiotensinogen, renin, aldosterone and ACE 
than lean women. Body weight reduction (approximately 5%) reduced angiotensinogen, renin 
and aldosterone levels and decreased ACE expression (117).  
 
1.5.4. Pancreas 
 
Renin mRNA was detected in the connective tissue surrounding the blood vessels and in 
reticular fibres within the islets of human pancreas. Renin protein was localized in the beta 
cells of the human islets of Langerhans and in endothelial cell of the pancreatic vasculature. 
AT2 receptor was detected in the beta cells of the human islets of Langerhans and also in 
endothelial cells of the pancreatic vasculature (118). The pancreatic RAS appears to regulate 
the secretion of pancreatic hormones. This finding and the overall functional relevance of the 
tissue RAS in the pancrease awaits further study and might account for the beneficial effects 
of ACE inhibitors and angiotensin II recpetor blocker therapy on the onset of type 2 diabetes. Introduction   13   
 
1.6. Homologues of ACE 
Apart from the angiotensin receptors (type I and II), a new member of RAS has been 
unraveled by genomic-based strategies which led to the discovery of ACE2, a human ACE 
homologue (119). ACE2 expression has been found in the heart, kidneys, testes, 
gastrointestinal tract, brain and lung (120-123). Unlike ACE, ACE2 hydrolyzes angiotensin I 
to angiotensin (1-9), angiotensin II to angiotensin (1-7) and bradykinin to [des-Arg
9]-
bradykinin (an inactive metabolite). The full length ACE2 cDNA encodes an 805 amino acid 
protein with a molecular weight of ~ 120 kDa. ACE2 is a zinc metallopeptidase sharing 42% 
sequence homology with ACE (119;121;124). The ACE2 protein sequence reveals a potential 
signal peptide at the N-terminus and a hydrophobic region near the C-terminus which likely 
serves as a cell membrane anchor. Like ACE, ACE2 is also an ectoenzyme capable of 
hydrolyzing circulating peptides and is susceptible to cleavage and secretion from the cell 
surface (121). However unlike ACE, ACE2 has only one isoform. The N-terminal domain of 
ACE2 has an active site while its C-terminal domain shows 48% sequence identity with 
collectrin. Collectrin is a renal specific type-1 transmembrane glycoprotein that lacks the 
metalloprotease catalytic domains of ACE and ACE2 (123) suggesting that collectrin has 
other physiological roles that are shared with  ACE2. Gene targeting studies indicates that 
ACE2 is an important regulator of cardiac function. ACE2 knockout mice exhibit severe 
reduction in cardiac contractility, increased angiotensin II levels in plasma and heart and 
upregulation of hypoxia genes (120). Cardiac dysfunction observed in these mutant mice is 
completely reversed by a second mutation that causes ACE deficiency. In sharp contrast to 
ACE, ACE2 does not convert angiotensin I to angiotensin II, and its enzymatic activity is not 
inhibited by ACE inhibitors. ACE2 probably counterbalances the enzymatic actions of ACE 
and thus might be a new target for hypertension. 
1.6. ACE as a signal transduction molecule 
 
 
To explain the mode of action of ACE inhibitors it was suggested that apart from inhibiting 
the formation of angiotensin II, ACE inhibitors increase the accumulation of bradykinin and 
also potentiates the responses to bradykinin, by inhibiting bradykinin B2  receptor 
desensitization (125;126). ACE inhibitors have been demonstrated to attenuate or partly 
reverse the bradykinin-induced translocation of the B2 receptor to caveolin-rich membranes 
and reactivate signalling events such as increase in intracellular calcium ions, activation of 
extracellular-regulated  kinases 1/2  in B2 receptor-desensitized cells (125) and thus was Introduction   14   
proposed that cross-talk might occur between ACE and the B2 kinin receptor (125-127). Many 
of the effects of ACE inhibitors in both animals and humans, such as the increase in 
endothelial NO synthase expression and improved vasodilator responsiveness can be inhibited 
by blocking the B2 kinin receptor (128). The question as to how this interaction between the 
two membrane proteins, ACE and B2 receptor occur, largely remains unanswered. Moreover 
angiotensin II levels are not decreased during long-term ACE inhibition and also other 
enzymes such as chymase can also generate angiotensin II and therefore the beneficial effects 
of ACE inhibitors cannot solely be attributed to a decrease in the generation of angiotensin II 
or accumulation of bradykinin, thus hinting towards the existence of an alternative pathway 
whereby ACE inhibitors might exert their positive actions on vascular system apart from the 
inhibition of angiotensin II production.   
For ACE per se to be a signal transduction molecule upon binding of an ACE inhibitor, it was 
hypothesized that ACE should be able to bind to soluble intracellular signal molecules or 
adaptor proteins. The ACE protein sequence revealed that somatic ACE has a short 
cytoplasmic tail which harbours five serine residues, one of which (Ser
1270 of the human 
sequence) is located in a highly conserved 13-amino acid sequence at the C-terminal end of 
the protein. ACE is phosphorylated by protein casein kinase 2 (CK2) at the serine residue 
1270 in the cytosolic tail of ACE.  In endothelial cells, CK2 which phosphorylates the 
enzyme has also been demonstrated to physically interact with ACE and the phosphorylation 
of ACE by CK2 has been shown to stabilize its localization in the plasma membrane as either 
the mutation of this residue or the inhibition of CK2 both enhance the cleavage/secretion of  
the enzyme (129). Interestingly, bradykinin, albeit to a lesser extent than an ACE inhibitor, 
increased ACE Ser
1270 phosphorylation and CK2 activity in endothelial cells lacking AT1 
receptors and bradykinin B2 receptors suggesting a signal transduction pathway for ACE that 
does not require B2 receptors. Angiotensin I did not increase the phosphorylation of the 
enzyme on Ser
1270 and CK2 activity. Apart from CK2, mitogen-activated protein kinase 
kinase 7 and the c-Jun NH2-terminal kinase (JNK) were also found to be associated with the 
cytoplasmic tail of ACE in endothelial cells. Following the CK2-dependent phosphorylation 
of Ser
1270, activity of ACE associated JNK is also increased in cells treated with ACE 
inhibitors and bradykinin. Activation of JNK results in the translocation of phosphorylated c-
Jun to the nucleus, and enhanced binding of the activator protein-1 transcription factor to 
DNA, followed by the increased expression of ACE (130) and cyclooxygenase-2 (COX-2) 
(131). This signalling pathway has been demonstrated in primary cultures of human 
endothelial cells and also in mice. The identification of ACE as a signalling molecule  that 
can be activated upon binding of ACE inhibitors may account for some of the beneficial Introduction   15   
effects of these drugs on the cardiovascular system. The ACE/CK2/JNK pathway may not be 
the only ACE signalling pathway activated by ramiprilat  since in endothelial cells ACE also 
has been found to interact physically with other intracellular molecules including CaM kinase 
II, annexin 2, the phosphatase PPI, β-actin and the non-muscle myosin heavy chain IIA 
(MYH9) and needs further investigation. 
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1.8. Aim 
 
Clinical trials have established an increasingly important role for ACE inhibition in the 
treatment and prevention of cardiovascular disease, improvement in endothelial function and 
delaying the onset of type 2 diabetes. These relevant findings cannot be attributed only to the 
inhibition of angiotensin II formation or decreased bradykinin degradation as it is well known 
that chronic ACE inhibition nevertheless does not decrease angiotensin II levels. The 
mechanisms of ACE inhibitors underlying these effects are so far unclear and needs 
investigation and go beyond just the metabolism of the kinins. 
The aim of this study was to investigate the intracellular events implicated in ACE signalling 
in endothelial cells and monocytes/macrophages and the physiological relevance of ACE-
mediated signalling in these cells. Furthermore we set out to identify the downstream 
effectors of ACE signalling which might be responsible for the beneficial effects by ACE 
inhibitors in various clinical conditions. As ACE inhibitors have been reported to delay the 
onset of type 2 diabetes, investigation also assessed whether ACE inhibitors activate 
peroxisome proliferator-activated receptor gamma (PPARγ), which influences multiple genes 
involved in carbohydrate and lipid metabolism, via the ACE signalling cascade.Materials and methods    17
2.  Materials and Methods 
 
2.1. Materials 
 
All media, enzymes and buffer as well as antibiotics, which were used for the cell and organ 
culture, were from the company GIBCO Life Technology (Karlsruhe), fetal calf serum (FCS) 
from Life Technologies Inc., human serum AB from PAA laboratories, GmbH and the cell 
culture dishes by Falcon (Becton Dickinson).  
The monoclonal anti-body (MAB 4051) against the extracellular, N-terminal segment of the 
angiotensin-converting enzyme (ACE), related for the immunoprecipitation and the 
immunohistochemical experiments, was from Chemicon international (Temecula, APPROX). 
The monoclonal antibody (C78) used for Western blotting also
 recognized the N-terminal 
domain and was provided by Dr. Peter
 Bünning (Sanofi-Aventis, Frankfurt, Germany). The 
ACE monoclonal antibodies (clone 9B9, 3A5, and
 5F1) recognizing different epitopes of the 
N-terminal domain
 of the enzyme were from Chemicon International (Temecula, CA). The 
phosphospecific p-Ser1270 antibody was generated
  from the peptide sequence 
HGPQFGpSEVELR (position 1263 to 1275
 in human somatic ACE protein) by Eurogentec 
(Seraing, Belgium).
 The monoclonal (MAB575) as well as the polyclonal (PAB568) anti-
body against the cytoplasmic, C-terminal segment of ACE were generated in mice and rabbits  
immunized with a synthetic peptide corresponding to to amino acids 1250 to 1277 in the ACE
 
C-terminus. The serum from these immunized animals was further purified by affinity 
chromatography. The antibodies against CD31 and JNK-1 were from Santa Cruz 
Biotechnology,
  Inc. (Santa Cruz, CA). The beads for immunoprecipitation, protein A 
sepharose was from Amersham (Freiburg) and protein G Sepharose was from Zymed 
(Berlin).  
The radioactive nucleotide ([
32P  γ- adenosine triphosphate was from Hartmann analytics 
(Braunschweig).  Bradykinin as well as angiotensin I and II were from Bachem Biochemica 
(Heidelberg).  
The ACE inhibitor ramiprilat was provided by Aventis (Frankfurt/Main). The oligonucleotide 
for the polymerase chain reaction (PCR) was synthesized by, Biospring GmbH 
(Frankfurt/Main. The transfection reagent Superfect was from Qiagen (Hilden). 
Oligonucleotide chips were from Affymetrix. The plasmids related to split-ubiquitin assay 
were generous
  gifts from Dr. Nils Johnsson (Westfälische Wilhelms-Universität
  Münster, 
Münster, Germany). All
 other substances were obtained from Sigma-Aldrich (St. Louis,
 MO).  
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2.2. Cell Culture 
 
Human umbilical vein endothelial cells  (HUVEC) were isolated from fresh umbilical cords, 
using dispase as described (132) and cultured in endothelium cell medium MCDB 131 
(Invitrogen, Karlsruhe, Germany) with FCS (8%), L-glutamine (10 mmol/L), fibroblast 
growth factor (1 ng/mL), epidermal growth factor (0,1 ng/mL), endothelial growth-
stimulating factor from cattle brain (0.4%), penicillin (50 U/mL) and streptomycin (50 
µg/mL) on cell culture dishes coated with fibronectin. HUVEC’s were used from passages 
between 0-2 as ACE expression goes down with passaging of the cells(133). Porcine 
endothelial cells (PAEC) were isolated from fresh porcine aorta using dispase and cultured in 
growth medium containing a 1:1 mixture. MCDB 131 (Invitrogen, Karlsruhe, Germany) and 
M199 (PAA laboratory, Pasching, Austria) containing 14% FCS, EGF (0.05 ng/mL), bFGF 
(0.5 ng/mL), endothelial cell growth supplement (1.5 mg/mL), heparin (22.5 mg/mL), 
penicillin (50 U/mL) and streptomycin (50 µg/mL). Although the porcine endothelial cells no 
longer
 endogenously expressed ACE or functional AT1 and B2 receptors,
 they expressed a 
number of characteristic endothelial cell proteins
  (von Willebrand factor, CD31, the 
endothelial nitric-oxide synthase,
 and VE-cadherin). These cells were transfected stably either 
with human wild type ACE or with non-phosphorlatable ACE mutant, and thus developed 
into a cell line, in order to examine the effects of the ACE mutation on the intracellular signal 
transduction pathways and the posttranslational modification of ACE in endothelial cells. 
 
2.2.1. Monocyte isolation 
 
Peripheral blood was obtained from healthy donors (Blood bank, Frankfurt am Main) and 
mononuclear cells were isolated by Ficoll gradient centrifugation. CD14 positive monocytes 
were separated from the enriched pelleted cells by Easysep method (Stem cell technologies) 
according to manufacturer’s instructions. 95% of the monocytes thus obtained were CD14 
positive by FACS analysis. Resulting monocytes were cultured in Primaria cell culture dishes 
(Becton Dickinson), in RPMI medium supplemented with L-glutamine, penicillin-
streptomycin, 5% human AB serum from PAA, 1X non essential amino acids, 1X MEM 
vitamins (GIBCO,BRL), 1 mM sodium pyruvate (PAA) and 10 mM HEPES (GIBCO, BRL). 
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2.3. Stable transfection of endothelial cells 
 
High-passaged ACE deficient porcine aortic endothelial cells (PAEC) were stably transfected 
with wild-type ACE, S1253A, S1263A,
 or S1270A using calcium phosphate precipitation or 
electroporation. Cells stably overexpressing wild type ACE and mutant ACE, were cultured in 
presence of selection antibiotic Geneticin G418 (500µg/mL), so that only the positive clones, 
which carry the geneticin resistance cloned in transfection plasmid were selected. Individual 
clones were selected and ACE expression and enzyme activity was assessed by means of 
western blot and spectrophotometric enzyme assay (129).  
 
2.4. Adenoviral infection of human endothelial cells 
 
For the infection of endothelial cells, the cells were serum-starved (medium containing 0.1% 
BSA) for 4-6 hours. Cells were infected with recombinant adenoviruses expressing human 
wild-type ACE or nonphosphorylatable S1270A ACE for 4 hours in the same medium. Virus 
containing medium was removed and the cell monolayer was washed three times with PBS in 
order to remove any traces of virus and/or virus particles and full medium was added and 
cultured for 24 hrs and then used for experiments. 
 
2.5. Protein isolation and Western blot analysis 
 
Cultivated or native endothelial cells, monocytes  were lysed in Nonidet lysis buffer (20 
mmol/L TRIS/HCl, pH 8.0, 137 mmol/L NaCl, 25 mmol/L β-glycerophosphate, 10% (v/v) 
glycerol, 2 mmol/L sodium pyrophosphate, 10 nmol/L okadaic acid, 2 mmol/L sodium-
orthovanadate, 2 µg/mL leupeptin, 2 µg/mL pepstatin A, 2 µg/mL antipain, 2 µg/mL 
aprotinin, 10 µg/mL trypsin inhibitor, 44 µg/mL PMSF and 1% (v/v) nonidet P40 and placed 
on ice for 10 minutes and subjected to centrifugation (10000 g, 4°C, 10 minutes). The protein 
concentration of the supernatant was quantified by Bradford’s method (134) or by Amido 
black staining (135;136). Protein extracts (20-50 µg) were denatured by heating in Laemmli 
buffer (2% sodiumdodecylsulfate (SDS), 5% β-mercaptoethanol, 8.5 % glycerin, 0,002% 
bromine-phenol-blue and 63 mmol/L TRIS/HCl, pH 6.8) at 95°C for 5 minutes and separated 
by SDS-PAGE. The proteins were then subjected to electrophoresis (running buffer: 190 
mmol/L glycine, 0.1% SDS and 25 mmol/L Tris-HCl) and resolved for about 2 hours with 
approximately 35 mA/gel. Western blotting was performed using the tank blot technique onto  
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nitrocellulose membranes (Biorad, Munich, Germany) for 90 minutes, in transfer buffer ( 190 
mmol/L glycine, 25 mmol/L Tris-HCl and 20% methanol) with 250 mA per apparatus for 90 
minutes. The nitrocellulose membranes were stained with Ponceau S (0.2% w/v) to determine 
the quality of transfer and equal loading of the protein. After destaining with distilled water, 
the membranes were blocked in Tris buffered saline with tween (TBST, 200 mmol/L NaCl, 
50 mmol/L Tris-HCl, pH 7.5, 0.3% Tween-20) containing 3% BSA for 1 hour at room 
temperature. The membranes were incubated with the primary antibody (routinely diluted 
1:1000) in TBST containing 3% BSA overnight at 4°C. The membranes were then washed in 
TBST for 30 minutes at an interval of 10 minutes for 30-45 minutes. The membranes were 
blocked again for 1 hour. The secondary antibody coupled to horse-radish-peroxidase (HRP, 
1:10000 in TBST) was incubated with the membranes for 1-2 hours at room temperature and 
washed again. The proteins were visualized on X-ray films (Fuji RX-film), by enhanced 
chemiluminescence solution (ECL,  Amersham Pharmacia, Freiberg, Germany). For semi 
quantitative determination of protein expression, the films were densitometrically evaluated. 
In order to probe the membranes with alternative antibodies, the nitrocellulose membranes 
were incubated in Stripping buffer (67.5 mmol/L TRIS/HCl, pH 6.8, 100 mmol/L β-
mercaptoethanol, 2% (w/v) SDS) at 50°C for 30 minutes. After decanting the stripping buffer, 
membranes were thoroughly washed several times with TBST and then incubated with 
specific antibody and processed as described above.   
   
2.6. Immunoprecipitation  
 
Immunoprecipitation (IP) is employed to isolate protein of interest using a specific antibody 
which is subsequently pulled down using protein A/G Sepharose beads. Cells were lysed in 
1% Nonidet lysis buffer, and incubated on ice for 10 minutes. The lysate was centrifuged at 
10000 g (4°C for 10 min) and the supernatant was transferred into a fresh tube. All 
subsequent steps were performed at 4°C. Cell extract (30-40 µg) was kept aside to check for 
total expression of the protein of interest and the rest volume was used for 
immunoprecipitation. The cell lysate (300 µg) was subjected to preclearing with 30 µl protein 
A/G Sepharose beads (Santa Cruz Biotechnology, Heidelberg, Germany) and incubated for 
30-60 minutes at 4°C on a rotating wheel. The preclearing step, allows the clearing of the 
lysate of non-specific protein binding to the sepharose. The supernatant of the preclearing was 
used for immunoprecipitation with the specific antibodies. For this, 5 µg of the antibody of 
interest was added to the lysate. The mixture was incubated on the rotating wheel at 4°C, for 2  
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hours. Then 50 µl of protein A/G Sepharose beads were added and incubated with the sample 
for 1 hour on the rotating wheel at 4°C. The complex of antigen, antibody and sepharose was 
then pulled down by centrifugation at 10000 g (4°C for, 10 minutes) and washed three times 
with Nonidet lysis buffer. Finally, 30 µl of Laemmli buffer was added and the protein 
denatured at 95°C for 5 minutes. Briefly, the samples were centrifuged for 1 minute in a 
microcentrifuge at 10000g and the supernatants were separated by SDS-PAGE and Western 
blotting. 
 
2.8. JNK activity Assay 
 
To assess JNK activity, cells were serum starved for 24 hours prior to stimulation, and rinsed 
twice with ice-cold phosphate-buffered
  saline, and then lysed in Nonidet lysis buffer 
(20 mmol/L  Tris-HCl,
  pH 8.0,  containing 1% Nonidet, 137  mmol/L NaCl, 25  mmol/L β-
glycerophosphate,
 1 mmol/L sodium orthovanadate, 2 mmol/L Na2H2P2O7, 2 mmol/L EDTA, 
pH 8.0,
 10% glycerol, and protease inhibitors (100  µg/ml phenylmethylsulfonyl
  fluoride, 
1 µg/ml aprotinin, and 1 µg/ml leupeptin). The cell lysate was cleared by centrifugation at 
10000 g at 4
0C for 10 minutes. The supernatant was precleared by incubating with 30 μl  of 
Protein A/G sepharose beads for 30 minutes and centrifuged again for 10 minutes.  The 
supernatant was incubated with 5 µl of rabbit anti-JNK1 antibody
 (Santa Cruz Biotechnology, 
Santa Cruz, CA) for 1 h at 4 °C and
 then with 50 µl of protein A/G-Sepharose for another 1 
hour. The
 immunoprecipitates were washed twice with Nonidet lysis buffer
 and once with 
kinase buffer (25  mmol/L HEPES, pH 7.6,  20  mmol/L MgCl2, 20  mmol/L β-
glycerophosphate,
 0.1 mmol/L sodium orthovanadate, 2 mmol/L dithiothreitol). The kinase
 
assays were performed at 30  °C for 30  min using 2  µg of GST-c-Jun
  (Cell Signalling, 
Beverly, MA) as substrate as described earlier(137), 20  µmol/L ATP, and 5
 µCi of [ -
32P]dATP (Hartmann Analytic, Braunschweig, Germany) in 30  µl of
  kinase buffer. The 
reactions were stopped by the addition of 10μL of 3X Laemmli
  sample buffer, and the 
products were resolved by SDS-PAGE (10%).
  The incorporation of [
32P] phosphate was 
visualized by autoradiography and quantified by
 scanning
 densitometry. 
 
2.9. RNA isolation 
Endothelial cells were grown to 80-90% confluence and infected with either human somatic 
ACE or S1270A mutant ACE. Cells were washed with PBS to remove traces of serum. Cells 
were then lysed with TRI reagent (Sigma, Germany) and incubated at room temperature for  
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5-10 minutes to permit the dissociation of nucleoprotein complexes. Chloroform (0.2 mL per 
mL of TRI reagent) was added and the homogenate was shaken vigorously. The cell 
homogenates were further incubated at room temperature for 5 minutes and were centrifuged 
at 13000 rpm for 10 minutes at 2 to 8
0C. Following centrifugation, RNA is then precipitated 
from the aqueous phase by mixing with isopropanol (0.5 mL per mL of TRI reagent) and 
incubated at room temperature for 10 minutes followed by centrifugation at 13000 rpm for 
10 minutes at 2 to 8
0C. After the centrifugation, the RNA precipitate is then  washed once 
with 75% ethanol and again with 95% alcohol, and centrifuged each time at 10000 rpm for 5 
minutes at 2 to 8
0C. The resulting RNA pellet is air dried briefly in a fume hood and 
reconstituted with RNase-free water. The quantity of the purified RNA samples was 
determined by measuring the absorbance at 260 nm (A260) using a spectrophotometer and the 
purity by measuring the A260/A280 ratio. A ratio of ≥1.7 (260/280) indicates that the RNA is 
free from protein and deoxy ribonucleic acid. The overall quality of RNA preparation was 
assessed further by electrophoresis on a denaturing agarose gel and visualized by ethidium 
bromide staining.  
2.10. Gene array (Affymetrix) for expression analysis 
 
Gene arrays have become a powerful approach for many applications to name a few, for the  
determination of the expression profiles of genes and identification of sequence (gene 
mutation). We used the gene array to compare the profile of expression of the genes in 
endothelial cells overexpressing somatic ACE or non-phosphorylatable ACE S1270 mutant 
and treated with or without ACE inhibitor. Affymetrix’s gene chips are glass slide arrays 
manufactured using special photolithographic methods and combinatorial chemistry, which 
allow the oligonucleotide spots to be synthesized directly onto the array substrate. For the 
Affymetrix gene array, endothelial cells were stimulated and RNA was extracted. One cycle 
eukaryotic target labeling assay was used. Total RNA ( 10 µg) was first reverse transcribed 
using a T7-Oligo (dT) promoter primer in the first strand cDNA synthesis reaction. Following 
Rnase H-mediated second strand cDNA synthesis, the double-stranded cDNA was purified 
and served as a template in the subsequent in vitro transcription reaction. The in vitro 
transcription was carried out in the presence of T7 RNA Polymerase and a biotinylated 
nucleotide analog/ribonucleotide mix for complementary RNA (cRNA) amplification and 
biotin labeling. The biotinylated cRNA targets are then cleaned up, fragmented and 
hybridized to GeneChip expression arrays. The hybridized cRNA was then stained with a  
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Streptavidin-phycoerythrin conjugates and visualized with an array scanner. The experiment 
was performed three times with different batches of cells to limit experimental variations. 
 
 
2.12. Nuclear isolation of proteins 
 
Cells were stimulated for the indicated times and harvested in ice cold PBS with protease 
inhibitors. All the procedures was handled on ice. Cells collected in PBS with protease 
inhibitors were centrifuged briefly for 30 sec at 14000 g at 4
0 C. The cell pellets were 
resuspended in 100 μL of the buffer A (Hypotonic buffer: 10  mmol/L HEPES 7.9, 10 
mmol/L KCl, 0.1 mmol/L EDTA, 0.1 mmol/L EGTA), 1mmol/L DTT, 0.5mmol/L PMSF, 
and mixed gently with pipetting. The cell pellets were incubated on ice for 10 minutes and 7.5 
μL of  10% nonidet was added to lyse the cell membrane and incubated on ice for further 1 
min, vortexed and centrifuged briefly at 14000 g at 4
0 C for 1 minute. The supernatant (post 
nuclear fraction) was transferred to fresh eppendorf tubes. The resulting pellet was briefly 
washed with PBS with protease inhibitors by vortexing and centrifugation at 14 000 g at 4
0 C 
for 1 minute in order to remove the traces of the post nuclear fraction. The pelleted nuclei 
were resuspended in 30-50 μL of the buffer C (Hypertonic buffer: 20 mmol/L HEPES pH 7.9, 
0.4 mol/L NaCl, 1mmol/L EDTA, 1mmol/L EGTA, 10% glycerol), and incubated on ice for 
30 minutes, vortexing for 10 seconds every 10 minutes for 30 minutes. The insoluble fraction 
was removed by centrifugation at 14 000 g for 10 minutes at 4
0 C. The nuclear extracts were 
stored at -80
0C until analysed further. 
 
2.13. Electrophoretic Mobility Shift Assay (EMSA) 
 
This technique is used to study gene regulation and determining protein-DNA interactions. 
The EMSA technique is based on the observation that protein-DNA complexes migrate more 
slowly than free DNA molecules when subjected to non-denaturing polyacrylamide or 
agarose gel electrophoresis (138).  Monocytes were cultured for 4 days and treated thereafter 
with/without ramiprilat for 24 hours. Nuclear extracts were prepared as described above. 
Protein concentration was measured by the method of Bradford. The NF-κB binding protein 
was used according to the manufacturer’s instructions. Briefly, NF-κB oligonucleotide  was 
end labeled using γ
32P-ATP using Ready-to-go T4 Polynucleotide kinase (Amersham 
Biosciences, Germany) kit. Unincorporated nucleotide was removed from the DNA probe by 
using the G-25 spin columns (Amersham Pharmacia biotech, Germany). Briefly the column  
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containing the resin is vortexed gently. The cap is loosened and the bottom closure is snapped 
off and placed in a 1.5 mL eppendorf tube for support. The column is centrifuged for 1 minute 
at 3000 rpm. The column is placed in a fresh eppendorf tube and the labeled sample is applied 
on to the center of the resin bed and centrifuged again for 2 minutes at 3000 rpm. The purified 
sample collects at the bottom of the eppendorf tube. 1 μL of the sample is counted. Nuclear 
extracts of 5 to 10 μg were incubated with 20000 counts per minute of the labeled 
oligonucleotide in binding buffer (20% glycerol, 5mmol/L MgCl2, 2.5 mmol/L EDTA, 2.5 
mmol/L DTT, 250 mmol/L NaCl, 50 mmol/L Tris-HCl -pH 7.5) on ice for 30 minutes. Poly 
(dI-dC) was used as a non-specific competitor. The samples were then separated on a 6% 
denaturing gel. The gel was dried and subjected to autoradiography. 
 
2.14. Statistical analysis  
 
Data are expressed as mean ± SEM, and statistical evaluation
 was performed by using the 
Student’s t test for paired
 or unpaired data, one way ANOVA followed by a Bonferroni t test
 
or ANOVA for repeated measures, where appropriate. Values of
 P<0.05 were considered 
statistically significant. 
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3. Results 
 
3.1. ACE dimerization in endothelial cells 
 
ACE has been defined as a signal transduction molecule which upon binding to ACE inhibitor 
turns on a signalling cascade culminating in changes in the gene expression in endothelial 
cells, however the mechanism by which ACE inhibitor initiates this signalling cascade was 
not clear. It was hypothesized that ACE which is anchored to the membrane with a single 
transmembrane domain should dimerize preceding the downstream signalling events. 
Therefore, we sought to determine whether or not ACE dimerizes in endothelial cells and 
whether ACE dimerization is involved in ACE inhibitor-induced ACE signalling. We used 
porcine aortic endothelial
  cells stably overexpressing human somatic ACE which were 
subjected
  to native gel electrophoresis. Two forms of ACE were detected by native gel 
electrophoresis: 
 a dominant form of approximately 270 kDa (monomer)
 and a minor form of 
approximately 520 kDa, the putative dimer
  (Fig. 3). To confirm ACE dimerization in 
endothelial cells, experiments were also performed under nonreducing conditions. The ACE 
dimer (~ 520 kDa) was only detected in SDS- and DTT- free conditions suggesting the 
involvement of disulphide bonds in ACE dimerization. In the presence of SDS and at high 
temperature of 95
0C, only the lower monomeric ACE was detected, the reason being, large 
protein aggregates are destroyed by detergent-SDS and high temperature. Endothelial cells 
treated with trypsin which cleaves ACE at the C-terminal stalk region (139) resulted in the 
loss of both the 520- and the 270-kDa forms of ACE.  
 
 
 
 
 
 
 
 
 
Fig. 3: Dimerization of ACE under basal conditions and in the presence of ramiprilat. 
Representative Western blots showing somatic ACE monomers (M) and dimers (D) in lysates of ACE-
overexpressing porcine aortic endothelial cells treated with either solvent (S) or ramiprilat (R; 100 nM; 
7 min) (left side) or ACE overexpressing (+ACE) and ACE-deficient (-ACE) porcine aortic 
endothelial cells (right side). Experiments were performed under nonreducing conditions (-SDS-DTT). 
As a control, lysates were treated with trypsin (10 U/ml; 1 h) before adding nonreducing sample buffer 
or were heated for 10 min in Laemmli SDS sample buffer (+SDS +95°C) before analysis. 
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ACE inhibitors are reported to increase the expression of ACE in endothelial cells in a time-
dependent manner (130). However, stimulation of endothelial cells with ramiprilat (100μM; 7 
min) significantly increased the relative amount of 520-kDa ACE by 137± 11% (n=5; p 
<0.05) as compared to the controls treated only with the solvent (left panel, Fig. 3) suggesting 
that ramiprilat increases the dimerization of ACE in endothelial cells. 
 
3.2. Existence of ACE dimerization in living cells system. 
 
ACE dimers were reported to exist in reverse micelles (64), so to determine homodimer 
formation of ACE in living cells, split-ubiquitin system was used. For the split ubiquitin 
system, ubiquitin is split into an N-terminal domain (Nub) and into a C-terminal domain (Cub), 
and neither is recognized by the ubiquitin-specific proteases (Ubps). This assay is based on 
the association of the Nub and Cub of ubiquitin that are fused to the cytosolic domain of full-
length human ACE generating ACE-Nub and ACE-Cub. The C-terminal of ACE-Cub is fused to 
an Ura3p reporter protein whose first amino acid has been replaced by arginine (RUra3p) thus 
generating ACE-Cub-RUra3p (Fig. 4). Dimerization-induced association of Nub  and  Cub in 
cotransformants creates a native-like ubiquitin which is then recognized by ubiquitin-specific 
proteases cleaving RUra3p.  
 
 
 
Fig. 4:  Schematic representation 
of conditional degradation design. 
A,  The first amino acid of Ura3p 
enzyme is replaced by arginine 
(Rura3p) and fused to ubiquitin. The 
fusion protein is cleaved by the Ubps 
and the free Ura3p is degraded rapidly 
by the enzymes of N-end rule that the 
cells are uracil auxotrophic and 
resistant to the drug 5-fluro-orotic acid 
(FOA).  B,  A fusion containing ACE, 
Cub and the Rura3p is not cleaved by 
the Ubps. The fusion is active and cells 
are uracil prototropic and sensitive to 
FOA. C, Co-expression of  Nub and Cub 
fused to ACE leads to increased 
interaction and a native-like ubiquitin 
is formed which is cleaved. RUra3p is 
rapidly degraded. The protein-protein 
interaction between ACE monomers 
can be detected by the absence of 
growth on plates lacing uracil and by 
growth on plates containing FOA. 
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In this way, the split-Ub system provides a direct readout of the Nub-Cub association state 
indicating existence of dimer forms.  
To check for the expression of both ACE-Nub and ACE-Cub proteins, transformed JD53 cells 
were further analyzed by Western blotting. Cells coexpressing ACE-Nub and ACE-Cub were 
unable to grow on ura
- plates but expanded on 5-FOA plates, indicating that ACE forms stable 
dimers (and/or higher oligomers) in intact cells (Fig. 6). While cells expressing ACE-Cub and 
an unrelated construct in which the ubiquitin conjugating enzyme Ubc6 was fused to the N-
terminal  portion of Nub grew on ura
- plates but not on ura
+ and 5-FOA
+ plates, indicating that 
ACE and Ubc6 do not interact under these indications. To enhance the discriminating power 
of the assay system, two Nub mutants containing alanine (Nua) or glycine (Nug) in position 13, 
which have a lower affinity for Cub than wild-type Nub,  were also used. Using these modified 
probes, a strong interaction between ACE-Nua  or ACE-Nug and ACE-Cub,  was observed 
indicating the existence of  ACE dimers/oligomers in living cells (Fig. 5). 
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Fig. 5: Serial dilutions of JD53 cells 
coexpressing ACE-Nub, ACE-Nug, or 
ACE-Nua and ACE-Cub were spotted on 
plates lacking Trp/His (CTL), or uracil 
and 5-FOA (ura
- 5-FAO
-), or on plates 
containing uracil and 5-FOA (ura
+ 5-
FOA
+). Interaction between ACE 
monomers is indicated by cell growth 
on ura
+ 5-FOA
+ plates and growth 
inhibition on ura
- 5-FAO
- plates and 
vice versa. Similar results were 
obtained in three additional 
experiments. 
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3.3 ACE inhibitors induce dimerization of ACE in endothelial cells 
 
To investigate the effects of ACE inhibitor ramiprilat on ACE dimerization, endothelial cells 
were treated with the ACE inhibitor and then exposed to chemical cross-linkers DSS or BS3 
to stabilize the dimers formed. The chemical cross-linker BS3 (which is membrane 
impermeable and has a spacer arm of 11.4 Å) reacts with lysine residues. Cross-linking 
experiments were then followed by Western blotting to assess dimerization of ACE. 
Ramiprilat induced a rapid (within 2 min) 2-fold increase in the dimerization of ACE, which 
was maintained for up to 60 min (Fig. 6A). 
 
Fig. 6: Effect of inhibitors on ACE dimerization and phosphorylation in endothelial 
cells. Porcine aortic endothelial cells stably overexpressing human somatic ACE were treated with 
ACE inhibitors. A, Time course (2-60 min) of the ramiprilat (100 nM) induced dimerization assessed 
after chemical cross-linking. The cross-linking of ACE on the
 surface of confluent cells was performed 
at room temperature
 for 30 min using 1 to 2 mM DSS or BS3. After quenching the reaction
 with 20 
mM Tris-HCl, pH 7.4, for 15 min at room temperature,
  cells were lysed and immunoblotting 
performed. B, Phosphorylation of ACE on Ser
1270. Results were quantified by calculating the D/M 
ratio and comparing changes relative to the ratio detected in unstimulated endothelial cells (CTL) or 
by calculating the p-Ser1270ACE/ACE signal ratio by densitometry and comparing changes relative to 
the signal obtained in CTL cells. The bar graphs represent the results of four to six independent 
experiments; * p<0.05;** p <0.01 versus CTL. 
 
On binding of an ACE inhibitor to ACE, CK2 phosphorylates the Ser
1270 residue in the 
cytoplasmic tail, a process that initiates a cascade of signalling events (130). Therefore 
phosphorylation of ACE was also assessed in parallel experiments.  
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We observed the ramiprilat-induced phosphorylation of ACE was maximal at 2 min after 
treating the cells with inhibitor but decreased back to the baseline in the next 10 to 15 min 
(Fig. 6B).  
To exclude an artifact arising from ACE-overexpressing endothelial cells we performed 
experiments in primary cultures of human umbilical vein endothelial cells which 
endogenously express ACE, and we observed ACE inhibitor-induced dimerization of ACE 
(Fig. 7A). The mutation of Ser
1270 to alanine prevents the ACE inhibitor-induced 
phosphorylation of ACE and the subsequent ACE signalling (130). To assess whether ACE 
dimerization is dependent on phosphorylation of the cytoplasmic tail of ACE, we performed 
experiments in endothelial cells overexpressing the nonphosphorylatable ACE. We however 
observed that even in endothelial cells overexpressing the nonphosphorylatable S1270A ACE 
mutant, ramiprilat was able to induce the dimerization of ACE (Fig. 7B) suggesting that ACE 
dimerization is not dependent on the phosphorylation status of the cytoplasmic tail.  
 
 
 
 
Fig. 7. Effect of ACE inhibitors on dimerisation after cross-linking. Human umbilical vein 
endothelial cells were treated with ACE inhibitors and assessed for ACE dimerization after cross-
linking with BS3. A, Effect of ramiprilat (Rami) and enalaprilat (Enala; each 100 nM; 2 and 7 min) on 
ACE dimer formation. Equivalent loading of protein in each sample was verified by reprobing the 
blots for CD31. This blot is representative of four to six additional experiments. B, Effect of Rami 
(100 nM; 2 and 7 min) on ACE dimerization in porcine aortic endothelial cells stably overexpressing 
the nonphosphorylatable ACE mutant S1270A. Porcine aortic endothelial cells stably overexpressing 
human somatic ACE were used as a positive control (+ve CTL). 
 
 
 
 
 
 
A 
B 
7C T L 2 CTL min
M
D
CD31
Rami
7 2
Enala
7C T L 2 CTL min
M
D
CD31
Rami
7 2
Enala
CTL
+ve
CTL
Rami
7 2 CTL
M
D
CTL
+ve
CTL
Rami Rami
7 2 CTL
M
DResults   30
A similar dimerization of ACE was observed with other ACE inhibitors (i.e., enalaprilat, 
quinaprilat, captopril) (Fig. 8) but with varying efficacies. The effect of ramiprilat and other 
ACE inhibitors on the dimerization of ACE in ACE-overexpressing porcine endothelial cells 
was concentration-dependent with significant effects being observed using concentrations of 
10 nM or greater (Fig. 8), thus suggesting that the ACE inhibitor-induced dimerization of 
ACE is a specific effect of this class of compounds, rather than a unique property of   
ramiprilat and also that the increase in dimerization of ACE was dependent on the binding of 
a compound (ACE inhibitors).  
 
 
Fig. 8: Concentration-dependent effect of different ACE inhibitors on ACE 
dimerization. Confluent endothelial cells were treated with different ACE inhibitors and assessed for 
ACE dimer formation after chemical cross-linking. Representative western blots showing the 
concentration-dependent effects of ramiprilat, quinaprilat, captopril, and enalaprilat (0.1 nM-10 µM; 2 
min) on ACE dimerization. Similar results were obtained in three additional experiments. 
 
 
3.4. Effect of carbohydrates on ACE dimerization  
 
ACE is an extensively glycosylated protein. Numerous studies have demonstrated that 
glycosylation plays an important role in the folding of ACE and also affects the transport and 
enzyme release (140-142). Human somatic ACE is reported to form carbohydrate-mediated  
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dimers and ACE contains a specific carbohydrate-recognizing domain (143). To assess the 
role of carbohydrates in enzyme dimerization, we used the monosaccharides galactose or 
glucose. ACE-overexpressing porcine aortic endothelial cells were incubated with 10 µM 
galactose, 10 µM glucose, or 10 µM mannitol (as an osmotic control) for 30 min, prior to the 
addition of 100 nM ramiprilat for 2 min as we had observed robust rapid dimerization with 
ACE inhibitors after 2 minutes. The basal or ramiprilat-induced dimerization of ACE in 
endothelial cells was not influenced by galactose, glucose, or mannitol (Fig. 9). Furthermore 
the pretreatment of cells with the monosaccharides did not influence either the basal or the 
ramiprilat-induced phosphorylation of ACE on Ser
1270.  
 
Fig. 9: Effect of carbohydrates on the dimerization of ACE in ACE-overexpressing 
endothelial cells. Endothelial cells overexpressing human somatic ACE were pre-incubated with 
galactose (Gal), glucose (Glc), or mannitol (Man) (each 10 µM; 30 min). Representative western blot 
depicts the effect of pretreatment with monosaccharides on ramiprilat (R; 100 nM; 2 min)-induced 
dimerization of ACE. The results were quantified by calculating the cross-linked D/M ratio and 
comparing changes relative to the ratio detected in unstimulated endothelial cells (S, solvent). The bar 
graphs represents results obtained in four to six different experiments; *, p < 0.05; **, p < 0.01 versus 
CTL. 
 
3.5. Effect of monoclonal antibodies on ACE dimerization and shedding 
 
The carbohydrate recognition domain that was suggested to be important for ACE 
dimerization is reported to be recognized and thus shielded by the monoclonal antibody 9B9 
(143). To determine the effect of different monoclonal ACE antibodies (9B9, 3A5, 5F1, and 
C78) directed to different epitopes within the N-domain on ACE dimer formation, ACE-
overexpressing porcine aortic endothelial cells were incubated with the above mentioned 
antibodies and assessed for dimer formation (143).  
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Fig. 10: Effect of anti-ACE monoclonal antibodies on ACE dimerization.  A,  Effect of 
solvent (S), ramiprilat (R; 100 nM; 7 min), monoclonal antibodies to the ACE N domain C78, 9B9, 
3A5, and 5F1 (each 10 µg/ml; 7 min) and an unrelated monoclonal antibody (mAb; anti-caveolin-1), 
on ACE dimerization in ACE-overexpressing porcine aortic endothelial cells. B, Effect of 
pretreatment with solvent and antibodies 9B9, 3A5, and 5F1 (each 10 µg/ml; 4 h) on the ramiprilat (R; 
100 nM; 2 min)–induced dimerization of ACE assessed after chemical cross-linking. The bar graphs 
summarize the results of three to six independent experiments; * p < 0.05; ** p < 0.01 versus the 
respective buffer alone. 
 
The antibodies tested had no acute effect on ACE dimerization per se (Fig. 10A). The 
antibodies tested were not able to prevent the ramiprilat-induced dimerization of ACE in 
ACE-overexpressing porcine aortic endothelial cells (Fig. 10B).  
Anti-ACE monoclonal antibodies which are epitope specific, have been reported to enhace the 
shedding of ACE (144). To determine the shedding of ACE, endothelial cells were incubated 
with anti-ACE monoclonal antibodies. Among the anti-ACE antibodies used only the 9B9 
and 3A5 antibodies (but not 5F1) significantly enhanced the amount of ACE precipitated 
from the endothelial cell supernatant (Fig. 11), reflecting the enhanced cleavage/secretion of 
the enzyme. 
 
sACE
CR CRC RC R
Solvent 9B9 3A5
Solvent
CR C RC
250
* *
* *
0
500
s
A
C
E
(
%
 
C
T
L
)
R CR
9B9 5F1 3A5
5F1
sACE
CR CRC RC R
Solvent 9B9 3A5
Solvent
CR C RC
250
* *
* *
0
500
s
A
C
E
(
%
 
C
T
L
)
R CR
9B9 5F1 3A5
5F1
Fig. 11:  Effect of anti-ACE monoclonal 
antibodies on ACE shedding. Effect of the 
9B9, 3A5, 5F1 antibodies (each 10 µg/ml; 4 h) 
on the amount of soluble ACE (sACE) 
recovered from the supernatant of endothelial 
cells. The culture medium was collected and 
centrifuged (for the precipitation of the 
detached cells) and subjected to 
immunoprecipitation. The bar graph represents 
data from three to six independent experiments; 
* p < 0:05.  
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3.6. Ramiprilat-induced dimerization initiates ACE signalling in CHO cells 
 
Glu
362 in the N-domain and Glu
960 in the C-domain are essential catalytic residues, and the 
His doublets 361/365 and 959/963 are most likely involved in the binding of Zn
2+ (57).  To 
determine whether the active sites are necessary for the dimer formation, CHO cells were 
stably transfected with either wild-type ACE or different ACE mutants; two with an 
inactivated N-domain (NHis and NGlu), two with an inactivated C-domain (CHis and CGlu), and 
one mutant with interfering mutations in both the N and C domains (N+CGlu). Mutation of the 
glutamyl residues within the C and/or N domains (NGlu, CGlu, and N+CGlu) did not have any 
effect on the ramiprilat-induced dimerization of ACE or on its phosphorylation on Ser
1270 
(Fig. 12A and B). Replacement of the two histidyl residues within the C domain of ACE 
(CHis) however attenuated the basal formation of ACE dimers as well as Ser
1270 
phosphorylation of the ACE mutant, whereas the NHis mutant did not show any change in  
dimerization and increased basal Ser
1270 phosphorylation in CHO cells overexpressing these 
mutants (Fig. 12 A and B).  
 
Fig. 12: Effect of ramiprilat on dimerization and phosphorylation of NHis amd CHis 
mutants. A, Representative Western blot showing the effect of solvent (S) and ramiprilat (R; 100 
nM; 2 min) on ACE dimerization. B, Effect of ramiprilat (R; 100nM) on phosphorylation at Ser
1270 in 
CHO cells overexpressing human somatic ACE (wtACE) or NHis and CHis mutants. The monomeric 
(M) and the dimeric (D) forms of ACE are indicated. The bar graphs summarize results obtained in 
four to six independent experiments; **, p < 0.01 versus basal wild-type ACE dimerization or 
phosphorylation. 
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ACE signalling involves the phosphorylation of Ser
1270 residue, leading to the activation of 
JNK (130). The effects of ramiprilat treatment on CHO cells expressing wild-type ACE were 
similar to those observed in cells expressing NHis, or any of the Glu mutants (NGlu, CGlu, and 
N+CGlu ; Fig. 13).  However ramiprilat was unable to activate JNK in CHis expressing cells 
(Fig. 13), indicating that ramiprilat was able to elicit signalling when the two His residues 
mediating Zn
2+ binding of the active site in the C-domain were present. 
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Fig. 13: Effect of ramiprilat on 
signalling by ACE mutants. 
Autoradiography of 
32P-labeled c-Jun 
and statistical analysis showing the 
effect of solvent (S) and ramiprilat 
(R; 100 nM; 7 min) on the activity of 
JNK immunoprecipitated from CHO 
cells overexpressing human somatic 
ACE (wt-ACE) or one each of the 
NHis, CHis, NGlu, CGlu, or N+CGlu 
mutants. To ensure equal 
immunoprecipitation of JNK, blots 
w e r e  r e p r o b e d  w i t h  a n  a n t i b o d y  
against JNK. The bar graph 
summarizes the results obtained from 
four independent experiments; * p < 
0.05 versus respective solvent; §, p < 
0.05; §§, p <0.01 versus basal JNK 
activity in cells expressing wild-type 
ACE. Results   35
 
 
3.6. Divergent gene expression induced by ramiprilat in primary               
endothelial cells 
 
 
ACE signalling leads to the activation of JNK/c-Jun pathway and the expression of ACE and 
COX-2 (131). To identify the genes affected by ramiprilat-induced dimerization and 
consequent ACE signalling, DNA microarray was used. Human umbilical vein endothelial 
cells were multi-passaged to ensure that these cells did not posses B2 receptor and had very 
little endogenous ACE as both ACE and B2 receptor levels diminish with passaging the cells. 
Wild type ACE or the non-phosphorylatable S1270 ACE mutant was then overexpressed in 
these endothelial cells. Briefly, human umbilical vein endothelial cells overexpressing either 
human somatic ACE and/or the non-phosphorylatable S1270 ACE mutant were treated with 
ramiprilat for 24 h and 48 h (Fig. 14). Total RNA was extracted from cultured cells and the 
integrity of RNA was assessed by visualization of ethidium bromide-stained gels. After 
prehybridisation, the labeled cDNA probes were hybridized onto Affymetrix oligonucleotide 
microarray. The relative expression level of each gene was determined by comparing the 
signal intensity of each gene in the array after background subtraction and normalization to 
the housekeeping genes. Genes were grouped depending on their expression levels in the 
control and treated samples in the cells expressing the wild-type ACE and not in the cells 
overexpressing the nonphosphorylatable mutant ACE which was the criteria for ACE 
signalling. Upregulation or downregulation of genes was considered if the magnitude of 
change was at least 4-fold in three independent experiments. 
Twenty-one genes were identified out of which seven genes were upregulated and fourteen 
were downregulated (Table. 2) by ramiprilat in endothelial cells expressing human somatic 
ACE but not in endothelial cells expressing the non-phosphorylatable S1270 ACE mutant. 
The genes which were regulated belong to different classes of molecular functions as 
tabulated (Table. 2). All of the genes, whose induction was four fold changed, were selected 
for further analysis. 
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Fig. 14:  Schematic representation of the protocol followed for the DNA microarray. 
Human umbilical vein endothelial cells expressing human somatic ACE or non-phosphorylatable 
S1270 mutant ACE were treated with ramiprilat for 24 h and 48 h. Total RNA was isolated and 
hybridized to Affymetrix oligo chips. All microarray analysis were performed with three completely 
different cell batches to ensure the reproducibility of results. 
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Activity Gene  Accession 
number 
Function 
Upregulated  Cellular retinol binding 
protein 1 
NM_002899 Intracellular transport of 
retinol 
  P57KIP2  D64137  Negative regulator of cell 
proliferation 
  CIS2 (STAT induced 
STAT inhibitor-2) 
AB004903 Negative  regulator  of 
IGF1/ growth hormone 
signalling pathway 
 CD26 
(Dipeptidylpeptidase IV) 
M74777 Peptidase,  T-cell 
activation 
 SOX-4  AI989477  Transcriptional  activator 
 CC-1(small  inducible 
cytokine subfamily A) 
NM_004166 Cytokine-cytokine 
receptor interaction 
  G8   NM_016947 No known function 
 
Downregulated  Interleukin 8  NM_000584 Chemotactic factor for 
neutrophils, basophils  
and T-cells  
 Mitofusin  2  NM_014874 Transmembrane 
mitochondrial GTPase 
  Cyclin F  NM_001761 Regulation of cell cycle 
  Cyclin E2  AF112857  Regulation of cell cycle 
 BRCA2  and  CDKN1A 
interacting protein 
NM_016567 Involved in double-strand 
break repair and/or 
homologous 
recombination 
  Metallothionein 1H  NM_005951 Binds to various heavy 
metals 
 Kinesin-like  6  (mitotic 
centromere associated 
kinesin  
U63743 Associates  with 
centromeres at early 
prophase 
  BRCA1 (Breast cancer 1, 
early onset) 
NM_007295 DNA repair 
  Kinesin-like 7  NM_020242 Associates with 
microtubules 
  Survivin (baculoviral IAP 
repeat-containing 5) 
NM_001168 Inhibitor of caspases 3 & 
7 
  Forkhead box M1  NM_021953 Transcriptional activatory 
factor 
  RacGAP 1  AU153848  Electron transporter 
activity 
  Cell division cycle 25 C  AF277724  Tyrosine protein 
phosphatase required for 
progression of the cell 
cycle 
 PRO2000  protein  NM_014109 Nucleoside-triphosphatase
 
Table. 2: List of genes screened through microarray analysis. 
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3.7. Expression patterns of selected genes in human endothelial cells 
 
Post transcriptional mechanisms could contribute to regulation of specific gene products. 
Therefore, a subset of genes detected by the gene array was analyzed by Western blot to 
check for their expression at the protein level. Fig. 15A shows the effect of ramiprilat 
treatment on the expression profiles of upregulated genes in the microarray data (SOX4, 
CRBP1, CCL14, p57KIP2). Fig. 15B shows the effect of ramiprilat on the downregulated 
genes-RacGap1, Survivin, FOXM1, BRCA1 and CDC25 at the protein level in endothelial 
cells overexpressing wild-type ACE. Surprisingly, in contrast to gene array results, there was 
no significant differences between the untreated control and ramiprilat (Rami; 100 nM; 24-48 
h) treated cells. Although the expression of these genes was substantial enough to be detected 
by Western blot analysis, we were not able to reproduce similar effects seen in the gene array.  
 
 
Fig. 15: Effect of ramiprilat on the expression profiles of modulated genes. Briefly, human 
umbilical vein endothelial cells overexpressing wild type ACE were treated with ramiprilat (Rami; 
100 nM) for 24 h and 48 h. The cells were harvested and the whole cell lysate was analysed by 
Western blot. A, representative blots showing the expression  of  upregulated genes SOX4, CCL14, 
p57KIP2 and B, downregulated genes RacGap1, Survivin, FOXM1, BRCA1 and CDC25 in three to 
five independent experiments. 
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3.8. Ramiprilat enhances cellular retinol binding protein-1 levels  in human  
       Plasma 
 
As several other cells and tissues also possess fully functional RAS, we screened plasma 
samples from healthy volunteers as well as from patients manifest with coronary artery 
disease and also from diabetic patients for the genes identified in the microarray. We observed 
that cellular retinol binding protein-1 (CRBP-1) was detectable albeit at low levels in plasma 
from patients (Fig. 16A). 
 
 
Fig. 16: Effect of ramiprilat on the CRBP-1 levels in human plasma. Plasma from the 
patients with coronary artery disease treated with/without ramipril, diabetic patients and healthy 
subjects were analyzed for CRBP-1 by Western blot. A, Representative Western blot showing the 
levels of CRBP-1 in treated coronary artery disease patients as opposed to untreated control patients 
and healthy subjects. Human testis protein lysate was used as a positive control. B, Blot showing 
CRBP-1 levels in diabetic patients compared to healthy subjects. The bar graph represents the percent 
increase in CRBP1 levels in plasma. ** p < 0.01. 
 
However ramipril markedly enhanced the levels of CRBP-1 in the plasma of coronary artery 
disease patients as compared to the untreated patients as analyzed by Western blotting (Fig. 
16A). CRBP-1 levels were also decreased in the plasma of type II diabetic patients compared  
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to healthy subjects (Fig. 16B). It is worth noting that the treatment of coronary artery disease 
patients with ramipril, enhanced the plasma CRBP-1 levels by 150% compared to healthy 
control subjects. 
 
On the basis of gene array results, we analyzed the effects of ramiprilat on CRBP-1 
expression. In contrast to the gene array results, wherein ramiprilat increased the gene 
expression of CRBP-1 by four fold, ramiprilat had no significant modulatory effect on the 
CRBP-1 expression at the protein level in primary human endothelial cells expressing the 
wild-type ACE. Next we investigated differences in the expression pattern of CRBP-1 in 
endothelial cells overexpressing the wild-type ACE or the non-phosphorylatable S1270 
mutant ACE and the effect of ramiprilat on CRBP-1. There was no difference in the 
expression pattern of CRBP-1 between endothelial cells overexpressing wild-type ACE (Fig. 
17A) and those overexpressing non-phosphorylatable S1270A mutant ACE (Fig. 17B) and 
also ramiprilat had no modulatory effect in CRBP-1 expression in either these endothelial 
cells overexpressing wild- type ACE and the mutant form of ACE.  
Fig. 17: Effect of ramiprilat on the expression of CRBP-1 in endothelial cells. Human 
umbilical vein endothelial cells expressing ACE were treated with ramiprilat for 24 h and 48 h and 
CRBP-1 expression was assessed in whole cell lysate by Western blot A, representative western blot 
showing the effect of solvent (CTL) and ramiprilat (R; 100 nM, 24 h and 48 h) on CRBP-1 expression 
in endothelial cells overexpressing the wild-type ACE and B, in endothelial cells overexpressing the 
non-phosphorylatable S1270 ACE mutant.    
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3.9. CRBP-1 overexpression increases the activity of retinoid X receptor 
(RXR) and PPAR response element (PPRE) promoter in endothelial          
cells 
 
As we failed to observe any regulation of CRBP-1 protein expression by ramiprilat in 
endothelial cells, we next sought to investigate the promoter activation of retinoid X receptor 
element (RXRE) in endothelial cells overexpressing CRBP-1.  Since physiologic retinoic acid 
receptor (RAR/RXR) activation is dependent on the retinoic acid transported by CRBP-1, we 
next sought to determine whether CRBP-1 overexpression influenced retinoid X receptor 
element (RXRE) activity in endothelial cells. Porcine endothelial cells overexpressing ACE 
were transfected with histidine tagged CRBP-1 (His-CRBP1). Control cells were transfected 
with green fluorescent protein (GFP). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 18. Effect of overexpression of CRBP1 on the activity of RXRE in endothelial cells. 
Endothelial cells overexpressing his-CRBP1 were transfected with RXR promotor constructs and 
stimulated with 9-cis-retinoic acid (9 cis-RA; 1μM), all-trans-retinoic acid (AT-RA; 1μM) for 24 
hours. Histogram showing the relative RXRE luciferase activity.  
 
 
Overexpression of CRBP-1 in endothelial cells was associated in increased activity of RXR in 
response to stimulation by 9-cis- retinoic acid (1μM) treated for 24 hours. 9-cis-retinoic acid  
which activates both RXR and RAR family of receptors increased the RXRE activity by 1.9 
fold in cells overexpressing CRBP-1 when compared to the cells transfected with GFP alone. 
In cells overexpressing CRBP-1, 9-cis-retinoic acid increased the RXRE activity by 1.7 fold 
compared to the solvent control (Fig. 18). 
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Fig. 19. Effect of overexpression of CRBP1 on the activity of PPRE in endothelial cells. 
Endothelial cells overexpressing CRBP-1 were transfected with PPRE promotor constructs and 
stimulated with 9-cis-retinoic acid (9 cis-RA; 1μM), rosiglitazone (Rosi: 100 nM) for 24 hours. 
Histogram showing the relative PPRE luciferase activity. Activity of PPRE is normalized to the 
relative luciferase activity of the controls.  
 
 
PPARγ after binding to a ligand, forms heterodimers with the retinoid X receptor (RXR) and 
binds to a peroxisome proliferator response element (PPRE) in a gene promoter, leading to 
the regulation of the gene transcription (145). We next sought to determine if there is 
promoter activation of PPRE in endothelial cells overexpressing CRBP-1. We observed an 
increase in PPRE luciferase activity in response to its ligand rosiglitazone (Rosi; 100 nM) by 
1.9 fold compared to solvent control in cells overexpressing GFP (Fig. 19), while 
rosiglitazone increased the PPRE activity by 4 fold in cells overexpressing CRBP-1 compared 
to cells not expressing CRBP-1 at all. Together these results suggest that overexpression of 
CRBP-1 influences the RXR and PPRE activity probably by increased availability and/or 
transport of retinol derivatives which serve as ligands for RXRE/PPRE. 
 
 
3.10. ACE signalling in human monocytes 
 
Although the ACE signalling pathway (ACE/CK2/JNK) was first demonstrated in endothelial 
cells, ACE signalling pathway has not been addressed in monocytes/macrophages which 
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possess functional local RAS. Circulating monocytes, which adhere to endothelial cell 
lesions, differentiate within the vascular wall to ACE-containing macrophages or foam cells 
with increased local synthesis of ACE and angiotensin II promoting atherosclerosis. No clear 
data is available on the mechanistic action of ACE inhibitors on monocytes/macrophages in 
reducing the events of atherosclerosis.   
 
 
 
 
Fig. 20: ACE expression in monocytes in culture. Peripheral blood monocytes were isolated 
from whole blood and CD14+ monocytes were cultured with 5% human serum. A, Representative 
Western blot showing increase in ACE expression with time in culture. Endothelial cells 
overexpressing human somatic ACE was used as positive control. This blot represents results from 3 
different experiments. B, Autoradiography of 
32P labeled c-Jun showing the effect of solvent (CTL) 
and ramiprilat (Rami; 100 nM; 2 and 7 min) in four days old ACE expressing monocytes. Bar graph 
summarizes data from 3 independent experiments; *, p < 0.05. 
 
 
We first sought to study the expression levels of ACE in monocytes in culture. Substantial 
ACE expression increases with increase in time of culture, as seen from four days old 
monocytes cultured with 5% human serum (Fig. 20A). To investigate ACE signalling in 
monocytes, we assessed the ability of ramiprilat to activate JNK in ACE expressing 
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monocytes. Ramiprilat (Rami; 100 nM, 2 and 7 min) was able to increase the phosphorylation 
of c-Jun thus indicating the activation of JNK in ACE expressing human monocytes (Fig. 
20B). Thus these results suggest the existence of ACE signalling in monocytes.  
 
 
3.11. Effect of ramiprilat on nuclear peroxisome proliferator-activated 
receptor gamma (PPARγ) levels in human monocytes 
 
 
One of the most intriguing and clinically relevant findings related to RAS inhibition using 
either ACE inhibitors or AT1 receptor antagonists is their ability to delay the onset of type 2 
diabetes. The mechanisms underlying this effect are not clear but may be related to the 
activation of PPARγ, a nuclear receptor that influences the expression of genes involved in 
carbohydrate and lipid metabolism (40). Enalapril activated PPARγ in aortae from 
apolipoprotein E-deficient mice (146) and also it was reported that certain angiotensin 
receptor blockers, like telmisartan induces PPARγ activity (147;148). Therefore we next 
sought to investigate if ACE inhibitors activate PPARγ in human monocytes cultured with 
human serum. Ramiprilat at 100 nM elicited a 1.7 fold increase in PPARγ levels in the 
nuclear extracts (Fig. 21A) which was comparable to the increase in PPARγ levels by potent 
agonist of PPARγ, rosiglitazone (100 nM; Fig. 21B). Ramiprilat (100 nM) was able to 
increase the PPARγ levels similar to rosiglitazone (100 nM) which is a potent agonist of 
PPARγ (Fig. 21B). The increased PPARγ levels were seen in the nuclear extracts of 
monocytes treated with ramiprilat but not in whole cell lysates suggesting that ramiprilat 
might increase the concentrations of PPARγ into the nucleus or diminish its degradation to 
increase the availability of PPARγ to result in expression of genes related to anti- 
inflammation in these cells. 
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Fig. 21: Effect of ramiprilat on PPARγ levels in human monocytes. Human monocytes were 
cultured in 5% human serum for four days and treated thereafter with ramiprilat for 24 h. A, 
Representative blot showing the effect of ramiprilat (Rami; 10, 30, 100 nM) on PPARγ levels in 
nuclear extracts of human monocytes. Bar graph summarizes the results from three different 
experiments. B, Blot showing the increase in PPARγ levels by ramiprilat compared to rosiglitazone at 
100 nM each. Blots were reprobed for equal loading on each lane for βactin. PPARγ levels were 
normalized to loading control βactin. 
 
 
We next hypothesized that ramiprilat might increase the levels of 15-deoxy-D-12,14-
prostaglandin J2 (15dPGJ2) which is a natural ligand for PPARγ via cyclooxygenase enzymes 
in monocytes and also it was previously demonstrated that binding of an ACE inhibitor leads 
to the activation of JNK/c-Jun pathway and increase in the expression of ACE and COX-2 
(131). To determine whether COX-2 expression is increased in monocytes, human monocytes 
were cultured for four days with human serum and treated with ramiprilat for 24 and 48 h. 
Under basal conditions, COX-2 expression per se diminishes with time in culture, however 
ramiprilat prevented the diminution in the relative levels of COX-2 uptp 48 hours of treatment 
(Fig. 22). However we failed to observe any modulation in the levels of 15dPGJ2 as the 
15dPGJ2 levels were too low to be detected by ELISA.  
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3.12. Effect of ramiprilat on nuclear PPARγ levels in human endothelial 
cells 
 
To explore the possibility of  similar observation seen in human monocytes with regard to 
increase in nuclear PPARγ levels in endothelial cells as well, human umbilical vein 
endothelial cells overexpressing somatic ACE were treated with ramiprilat (100 nM) for 24 h. 
Ramiprilat increased the nuclear levels of PPARγ in endothelial cells as well. The effect of 
ramiprilat was more pronounced in increasing the PPARγ1 than γ2 levels (Fig. 23).  
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Fig. 22: Effect of ramiprilat on COX-2 
expression in human monocytes. Human 
CD14+ monocytes were cultured in the 
presence of 5% human serum and treated 
with solvent (CTL) and ramiprilat (R; 100 
nM; 24 and 48 h). Representative Western 
blots showing the expression of COX-2 
under basal conditions and in the presence of 
ramiprilat. COX-2 levels were normalized to 
βactin. Bar graph summarizes the results 
obtained from five to seven different 
experiments.  
 
Fig. 23: Ramiprilat enhances PPARγ 
levels in human endothelial cells. 
Human umbilical vein endothelial cells 
overexpressing wild-type ACE were 
treated with ramiprilat (Rami) and 
rosiglitazone, (Rosi) each at 100 nM and 
treated for 24 h. Nuclear extracts of treated 
monocytes were analyzed for PPARγ. 
Human adipocyte whole cell lysate was 
used as a positive control. Blots were 
reprobed to check for equal loading for 
βactin. PPARγ1 levels were normalized to 
βactin. Bar graph represents data from 3 
different experiments. Results   47
The substantial increase in nuclear PPARγ levels by ramiprilat as comparable to rosiglitazone           
was unfortunately not so reproducible owing to the very low levels of PPARγ in human 
endothelial cells and also due to high variability between each batch of cells from human 
umbilical cords.  
To investigate the effects of ACE inhibitors on transcriptional activation of PPARγ, porcine 
aortic endothelial cells overexpressing ACE were transfected with a GAL4 reporter construct 
(i.e., 3X PPRE-TK-Luc). The transfected cells were treated with ramiprilat, rosiglitazone each 
at 100 nM and rosiglitazone (100 nM) in combination with PPARγ antagonist GW9662 
(30µM) for 36 h. Compared with controls, rosiglitazone markedly activated the luciferase 
activity of the reporter gene, while combination treatment of PPARγ antagonist and 
rosiglitazone had a mild effect but ramiprilat did not have any effect on the promoter activity 
of PPAR response element (Fig. 24). These results suggest that the ramiprilat-induced 
activation of PPARγ levels could be through an independent mechanism and not by direct 
transcriptional activation of the promoter. 
 
 
 
 
 
 
 
 
 
 
 
3.13. ACE inhibitor regulates adiponectin, a downstream target of PPARγ  
 
Adiponectin is approximately 30 kDa plasma protein that is found in multimeric complexes in 
the circulation at relatively high levels in healthy human subjects. Adiponectin protein is 
secreted specifically from adipose tissue (149;150). Adipokine adiponectin is known to exert 
anti-inflammatory and insulin-sensitizing effects and is a downstream target of PPARγ. Since 
we failed to observe any activation of PPARγ responsive element we hypothesized that there 
might be an increased heterodimerization between PPARγ and RXRα probably via CRBP-1.   
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activity by ramiprilat. Porcine 
aortic endothelial cells overexpressing 
ACE were transfected with PPRE X 3-
TK-Luc were treated with ramiprilat 
(Rami; 100 nM), rosiglitazone (Rosi; 
100 nM) and rosiglitazone (100 nM) in 
combination with PPARγ antagonist 
GW9662 (GW; 30µM) for 36 h. All 
cells were lysed for luciferase. The bar 
graph represents the relative luciferase 
activity, defined as the normalized 
luciferase activity in reference to that 
of vehicle- treated controls (CTL) and 
summarizes results from 4 different 
experiments: *, p < 0.05; ***, p < 
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Both the ACE inhibitors increased the relative amount of adiponectin secreted in the culture 
medium as analysed by Western blotting (Fig. 25). The supernatant harvested from the human 
adipocytes also had increased amount of soluble ACE compared to the ACE present in the 
whole cell lysate (Fig. 25).  
We were able to translate the in vitro observation in in vivo experiments as well. Ramipril 
treatment also enhanced adiponectin levels in serum from C57 black mice treated for 5 days, 
as analyzed by ELISA (Fig. 26A). We also analyzed adiponectin levels in the serum samples 
from ob/ob mice treated with ramipril (Rami; 5mg/kg/day), rosiglitazone (Rosi; 3mg/kg/day) 
and in combination (Rami+Rosi). The adiponectin levels in serum of the combination 
treatment in ob/ob mice were significantly higher than rosiglitazone or ramiprilat alone 
suggesting a synergistic effect (Fig. 26B).  
 
 
Fig. 26: Effect of ramipril treatment on plasma adiponectin levels. A, plasma from C57 
black mice (which were treated for 5 days with ramipril, 5mg/kg/day), was analyzed by ELISA for 
adiponectin. B, plasma adiponectin levels in Ob/Ob mice, as analyzed by ELISA. Ob/Ob mice were 
treated for 10 weeks with ramipril (Rami; 5mg/kg/day), rosiglitazone (Rosi; 3mg/kg/day) and in 
combination by oral gavage. * p< 0.05 ** p< 0.001 *** p< 0.0001 
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Fig. 25: Effect of ACE inhibitors 
on adiponectin in human 
adipocytes.  Human adipocytes were 
treated with ACE inhibitors ramiprilat 
(Rami; 30 nM, 100 nM), enalaprilat 
(Enala; 30 nM, 100 nM), Angiotensin 
II receptor blocker-telmisartan (Telmi; 
100 nM) and rosiglitazone (Rosi; 100 
nM) for 24 hours respectively. The cell 
supernatent was harvested and 
analyzed for adiponectin by Western 
blotting. Results   49
Adiponectin levels have been reported to be lower in patients with coronary artery disease 
compared to healthy counterparts (151;152). We next determined whether ACE inhibitor has 
any effect on adiponectin levels in plasma samples from patients with coronary artery disease 
treated with or without ramipril (5mg/day) and compared to healthy subjects. Ramipril 
enhanced the relative amount of adiponectin in plasma from patients with coronary artery 
disease treated with ramipril by 3.5 fold compared to either untreated patients with coronary 
artery disease or by 7.5 fold when compared to plasma adiponectin levels in healthy subjects 
(Fig. 27).  
 
Fig. 27: Effect of ramipril treatment on adiponectin in plasma from patients with 
coronary artery disease.  Plasma from healthy subjects, patients with coronary artery disease 
treated with or without ramipril was analyzed by Western blotting for adiponectin. Bar graph 
summarizes data obtained from five patients in each group. *** p < 0.0001.  
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3.14. NF- κB activation by ramiprilat in human monocytes 
 
Nuclear factor-κb (NF-κB) is an inducible transcription factor that plays a role in the 
expression of spectrum of genes involved in immune and inflammatory responses and cell 
survival. It has been suggested that many anti-inflammatory effects of PPAR’s might depend 
on the inhibition of the NF-κB signalling pathway (153). To elucidate the effect of ACE 
inhibitors on activation of NF-κB, electrophoretic mobility shift assay (EMSA) was 
performed. Nuclear extracts from human monocytes treated with ramiprilat (Rami; 10, 30, 
100 nM; 24h) did not show any strong DNA binding activity for NF-κB (Fig. 28)  as 
compared to monocytes treated with TNFα (10 ng/mL; 30 min). These results suggest that 
ramiprilat does have a slight inhibitory effect on activation of NF-κB. 
 
 
Fig. 28: Effect of ramiprilat on NF-κB activation: Human primary monocytes were cultured 
for 4 days in the presence of human serum and exposed to with or without ramiprilat (Rami; 10, 30, 
100 nM; 24h). Cells were harvested, nuclear extracts prepared, and EMSA performed using a 
radiolabelled oligonucleotide containing the consensus site for NF-κB. Representative autoradiograph 
demonstrating that ramiprilat, has no significant effect on NF-κB activation compared to positive 
control. Nuclear extracts from monocytes treated with TNFα for 30 min was used as a positive control. 
Specific NF-κB band is indicated by arrow. Bar graph is representative of two to three separate 
experiments. 
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4. Discussion   
 
4.1. ACE dimerization initiates ACE signalling in endothelial cells 
 
The findings of this study demonstrate that ACE occurs as a homodimer as well as a 
monomer in endothelial cells. Binding of an ACE inhibitor to the enzyme significantly 
enhances ACE dimer formation. The integrity of C-terminal active site of ACE seems to be 
the determining factor for ACE dimerization as the ACE-inhibitor induced dimerization as 
well as the ACE inhibitor-induced phosphorylation of ACE on Ser
1270 and the subsequent 
activation of JNK pathway was abrogated by the mutation of two critical histidyl residues that 
bind zinc ions. Given that dimer formation correlated with the time course of the inhibitor-
induced ACE phosphorylation on Ser
1270, the dimerization of ACE thus may be the initial step 
in the ACE signalling pathway recently identified in endothelial cells. 
Protein-protein interactions resulting in dimerization and heterodimerization are of central 
importance in the control of gene expression and cell function. Analysis of the quaternary 
structure of several membrane-bound and secretory proteins has demonstrated that  dimer or 
oligomer formation is an important event that is required for efficient intracellular transport of 
these proteins, enhances their efficacy and also might be important for signal transduction 
(154-156). Other type I membrane glycoproteins, such as the β-secretase (β-site amyloid 
precursor protein cleaving enzyme) are also able to dimerize and thus regulate their 
intracellular and/or extracellular functions (157). Similar to ACE, β-site amyloid precursor 
protein cleaving enzyme can be phosphorylated on a serine residue near its C-terminus and 
can also be cleaved from the cell surface (158). 
High molecular mass aggregates of ACE that might represent homodimers have been found 
during the purification of the enzyme from human lung (159) and also in in vitro experiments 
by using reverse micelles and ACE-expressing COS cells (143;160).  Mature somatic ACE 
has a calculated molecular mass of 149.7 kDa, due to the glycosylation of the enzyme, the 
molecular mass of the enzyme is between 170 and 180 kDa revealed by denaturing 
electrophoresis (161;162). Other forms of human somatic ACE exists as an immature form in 
intracellular compartments (~170 kDa) and a soluble form (~ 175 kDa) which is cleaved from 
the plasma membrane (163). ACE is synthesized as a single polypeptide precursor that 
matures in the Golgi apparatus by acquisition of complex-type oligosaccharides and is then 
inserted into the membrane. ACE has been shown to  exist in dimeric form in vitro (64;160) 
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Native gel electrophoresis is an excellent tool to detect oligomers and aggregates. By means 
of native gel electrophoresis, wherein the electrophoretic mobility of proteins depends 
primarily on both the protein’s charge and its hydrodynamic size, we found that ACE 
migrates not only as monomers but also as dimers. Results obtained from the split-ubiquitin 
assay revealed that ACE dimerization is more pronounced in living cells (yeast) than in in 
vitro assay system confirming that ACE forms functional dimers. Cross-linking of ACE on 
the surface of the endothelial cells indicated that ACE forms dimers on the cell-surface, albeit 
that the population of ACE dimers is relatively small as we could observe relatively low level 
of dimers formed and could be attributed to methodological problems related to the detection 
of  ACE dimers by the antibodies used in this study. Dimerization of proteins usually involves 
covalent and non-covalent interactions. The mechanism of ACE dimerization seems to be 
similar to the noncovalent interactions involved in dimerization of membrane proteins such as 
P-selectin (164) and ICAM-1 (165) but differs from dimerization of other membrane proteins, 
where disulfide links are involved, for example, platelet derived growth factor (PDGF) (166). 
 
Given that ACE forms dimers in endothelial cells, we next determined whether the binding of 
an ACE inhibitor to ACE has any effect on dimer/monomer population in the endothelial 
cells. Our results demonstrated that the treatment of endothelial cells with ramiprilat, 
increased the dimer/monomer ratio. The formation of ACE dimers also correlated well with 
the ACE inhibitor induced phosphorylation of the enzyme on Ser
1270. The ACE inhibitor-
induced phosphorylation of ACE is biphasic, that is the phosphorylation increased from 2 to 7 
minutes and elevation is maintained again after 6 to 48 hours (130). ACE-induced 
dimerization thus preceded in the phosphorylation of the Ser
1270 in the
 cytoplasmic domain as 
previously demonstrated (130) and activation of the signalling cascade culminating in 
changes in the endothelial gene expression (131). The formation of ACE dimers was also 
observed when cells were stimulated with enalaprilat, quinaprilat and captopril indicating that 
this is a specific effect by this class of compounds. ACE dimer formation was unequivocally 
observed in an endothelial cell line overexpressing human somatic ACE as well as in primary 
cultures of human umbilical vein endothelial cells that endogenously express ACE, indicating 
that the effects observed cannot be attributed to an artifact associated with the overexpression 
system. 
 
Somatic ACE is  principally N-glycosylated with a mixture of both N-acetyl-lactosaminyl 
(complex) sugars and oligomannosidyl or hybrid sugars (65;84;167). Somatic ACE harbours 
17 potential N-linked glycosylation sites. Ten such sites occur in the N domain, for which  
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carbohydrates constitute 37% of its molecular mass, while the C-domain has seven such sites 
(66;142;167;168). It has been previously suggested that ACE dimerization has been attributed 
to interactions between its carbohydrate side chains and a carbohydrate recognition domain at 
its N-domain that are sensitive to treatment with galactose (160), we therefore investigated the 
effects of galactose, glucose or mannitol on basal or the ramiprilat-induced dimerization of 
ACE. However, we were unable to find any significant interference of these monosaccharides 
with ACE dimerization. It has also been suggested that the 9B9 monoclonal antibody directed 
against the putative carbohydrate recognition domain region can interfere with ACE self-
association (143). Therefore we tested various antibodies directed to the epitopes of N-
domain of ACE on dimer formation. The monoclonal antibodies had no effect on the basal or 
ramiprilat-induced dimerization of ACE but displayed differential effects on shedding of the 
enzyme. It has been reported previously that the monoclonal antibodies directed to different 
epitopes of human ACE, induced shedding of the enzyme and also has been linked to   
inhibition of  dimerization (143). In our study, we observed that the shedding of the enzyme 
was apparent with monoclonal antibodies 9B9 and 3A5 as reported previously (143) but we 
failed to see any link between shedding and dimerization. The differences in the results 
observed, related to the effects on dimerization, by the authors (143) and our results is   
possibly due to the experimental model used to study dimerization as we used endothelial 
cells in culture and not reverse micelles (64) which might be a pseudo-physiological system to 
study dimerization. 
Dimerization plays an important role in the functioning of many membrane proteins 
(169;170). To determine whether dimerization of ACE is linked to the recently described 
ACE signalling cascade, which involves the ACE inhibitor-induced phosphorylation of the 
enzyme on Ser
1270 and subsequent activation of JNK pathway (129;130), we compared the 
effects of ramiprilat on the dimerization of the wild-type ACE as well as of the S1270A ACE 
mutant. Ramiprilat elicited dimerization of both the wild-type and the S1270A ACE, 
indicating that the phosphorylation of the cytoplasmic tail of the enzyme does not influence 
dimer formation but requires intact extracellular domains to form dimers. 
Although the N- and C-domains of ACE resulted as a consequence of gene duplication (73), 
there are marked functional differences between these two domains of ACE, despite the high 
degree of sequence homology. The rate of hydrolysis of various synthetic and natural 
substrates by the two domains differs, with the C-domain of human ACE  having higher 
catalytic constants for Hip-His-Leu, angiotensin I, bradykinin, and substance P, whereas the 
N-domain hydrolyzes LH-RH and the negative hematopoietic regulator N-Ac-Ser-Asp-Lys-
Pro at much higher rates (55;57;171). The C-terminal domain is more sensitive to chloride Discussion  54
activation (57;172). Most of the competitive ACE inhibitors bind tightly with the C-domain 
active center (173). The two domains of ACE differ also in conformation (174;175). The 
striking functional difference between the N- and the C-domains of ACE is found to be the 
conversion of angiotensin I which takes place preferentially within the C-domain and 
selective C-domain inhibition is adequate to prevent angiotensin I-induced vasoconstriction 
(176). Also evidence points out that the N-domain of ACE may be functionally less 
significant, as the RXP407 peptide which specifically inhibits the N-domain of ACE has no 
effect on blood pressure (177).  
We therefore sought to determine whether interfering with the dimerization of ACE affected 
the ACE inhibitor-induced phosphorylation of the enzyme and/or subsequent activation of 
JNK by using different C-or N-domain inactive ACE mutants. Different C- or N-domain 
inactive ACE mutants overexpressed in CHO cells revealed that the C-domain is more 
important for dimerization rather than the N-domain. Analysis of the inactivation of the C-
domain by mutation of the two essential Zn
2+ complexing histidyl residues of the HEMGH 
consensus sequence completely abrogated the enzyme’s ability to dimerize either under basal 
conditions or in response to ramiprilat. Mutation within the C-domain also abolished the 
inhibitor-induced signalling, in as much as we failed to observe ramiprilat-induced increase in 
Ser1270 phosphorylation and/or subsequent activation of JNK pathway. However, mutation 
of the N-domain did not affect ACE-inhibitor induced dimerization and subsequent ACE 
signalling. Given that N-domain bears a carbohydrate recognizing domain and has more 
putative glycosylation sites than C-domain (59;69;142), in this case N-domain was not found 
to be essential for dimerization. Although we do not know how ACE inhibitors can effect 
ACE dimerization via the C-domain, it is possible that their binding induces conformational 
changes that eventually result in the exposure of a dimerization domain, as has been reported 
for the ligand-induced dimerization of the epidermal growth factor receptor (178). 
Results of the present study suggests that the ACE inhibitor-induced dimerization of ACE, via 
the C-domain of the enzyme commences the ACE signalling pathway that involves 
subsequent activation of the JNK/c-Jun pathway and leads to changes in endothelial cell gene 
expression illustrated in Fig. 26. Discussion  55
 
Fig. 26: Scheme summarizing the ACE inhibitor-induced dimerization of ACE, via the C- 
domain of the enzyme, representing the initial step in the ACE signalling pathway that 
involves the activation of the JNK/c-Jun pathway and leads to changes in endothelial cell 
gene expression. 
 
 
4.2. Downstream effectors of ACE signalling pathway in endothelial cells 
 
ACE signalling results in the translocation of phosphorylated c-Jun to the nucleus and 
enhanced binding of the activator protein (AP)-1 transcription factor to the DNA, followed by 
the increased expression of ACE (130) and COX-2 (131). Increased ACE and COX-2 levels 
could be associated with improvement in endothelial cell function and has physiological 
relevance as increased ACE levels  have been demonstrated in lung tissue and plasma from 
rats treated with ACE inhibitor (179) and in the serum from patients who distinctly benefit 
from ACE inhibitor therapy (180). Prostacyclin production is significantly increased in  
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patients treated with ACE inhibitors and selective COX-2 inhibition attenuates the positive 
effects of ACE inhibitors on blood pressure (181).  
To identify the downstream effectors of the many beneficial effects of ACE inhibitors which 
cannot be attributed only to inhibition of angiotensin II generation (as angiotensin II levels are 
not decreased during long term ACE inhibitor therapy) and bradykinin degradation, we used 
DNA microarray technology. We identified 21 genes (in addition to ACE and COX-2) that 
are differentially regulated (7 upregulated and 14 downregulated) (Table. 1) by ramiprilat in 
endothelial cells expressing wild-type ACE but not in cells expressing a non-phosphorylatable 
ACE mutant (wherein Ser
1270 is replaced with alanine) which was the criteria for ACE 
signalling. In contrast to the gene array results, we failed to detect any difference between the 
solvent control and ramiprilat treated endothelial cells in the regulation of modulated genes. 
We failed to see any modulation of the expression levels of the selected genes by ramiprilat 
even after prolonged exposure to ramiprilat at the protein level, although the expression levels 
of the selected genes were substantial enough to be detected by Western blot considering that 
the protein expression levels take much longer time than the expression of genes.  
Cellular retinol binding protein 1 (CRBP-1) was upregulated by ramiprilat in endothelial cells 
overexpressing wild-type ACE by four fold in the microarray. However there was no 
difference in CRBP-1 expression per se between endothelial cells expressing wild-type ACE 
or the non-phosphorylatable ACE. Moreover we failed to see any modulation by ramiprilat on 
CRBP-1 levels in endothelial cells expressing either the wild-type ACE or the S1270A mutant 
ACE.  
Local functional RAS has been described in other cells and tissues so we screened for the 
plasma samples from healthy volunteers as well from patients with coronary artery disease for 
the genes identified in the microarray.  We observed that CRBP-1 was detectable at low levels 
in the plasma samples and also ramipril markedly increased the levels of CRBP-1. CRBP-1 
belongs to the fatty-acid binding protein (FABP) family. In humans, CRBP-1 is highly 
expressed in the ovaries, pituitary gland, testes, adrenal glands, and liver where it is much 
more abundant in hepatic stellate cells than in hepatocytes. Although the physiologic 
importance of CRBP-1 in the disease processes is largely unknown, it has been proven that 
CRBP-1 levels is decreased in various cancers (182;183). Therefore considering the 
molecular function and post-translation profiles of the regulated genes, we found Cellular 
retinal binding protein-1 (CRBP1) to be regulated distinctly by ramiprilat in human plasma 
from patients manifest with coronary artery disease, treated with ramipril. CRBP-1 levels 
were also diminished in plasma from diabetic patients as compared to the healthy subjects.  Discussion  57
However we do not know yet as to whether diabetic patients treated with ramipril also have 
enhanced levels of plasma CRBP-1 similar to coronary artery patients treated with ramipril.  
Although CRBP-1 levels were not regulated by ramiprilat in cultured endothelial cells, it is 
tempting to speculate that the plasma CRBP-1 might be contributed by other tissues such as 
adipose tissue, wherein a functional local RAS is present.  It needs to be investigated how 
ramiprilat regulates plasma CRBP-1 levels in human patients or whether ramiprilat acts on 
other tissues where there might be an active ACE signalling pathway.  
Retinoid signalling requires a prenuclear phase, which is regulated by CRBP’s. CRBP-1 is 
considered essential for vitamin A homeostasis. The most important physiologic functions of 
CRBP-1 is to bind to retinol from blood, esterification and intercellular transfer of retinol 
between cells, more so in between liver cells (184). CRBP-1 facilitates the retinoid transport 
from the cytoplasm into the nucleus and influences the ligand binding of the nuclear receptors 
(185;186). Therefore we assessed whether overexpressing CRBP-1 would have any effect on 
the activity of PPRE and RXRE. We found that in endothelial cells overexpressing CRBP-1, 
9-cis-retinoic acid increased the RXR activity and rosiglitazone increased the activity of 
PPRE suggesting that overexpression of CRBP-1 favours the conversion of retinol into 
retinoic acid which is the ligand for PPRE/RXR/RAR and promotes gene expression. 
However, the regulation of CRBP-1 by ramiprilat still needs further investigation.  
Fig. 27. Scheme illustrating the reliance of PPAR signalling on RXR/RAR. Retinol is 
transported bound to CRBP-1 and is converted to retinoic acid (RA), Retinoic acid binds to RA 
receptors (RARs) and the retinoid X receptors (RXRs). RXRs function as obligate heterodimer 
partners for PPARs. Upon binding to ligands, PPAR heterodimerizes with RXR and regulates the 
expression of genes. 
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4.3. ACE signalling in monocytes 
 
Atherosclerosis is initiated by dysfunction of endothelial cells at lesion-prone sites in the 
walls of arteries, promoting a proinflammatory vasculature and results in monocyte 
infiltration into the arterial intima (187). These monocytes then differentiate into 
macrophages, which then internalise large amounts of low-density lipoprotein forming 
cholesterol-laden macrophages called foam cells (188). Given the clinical significance of   
activated monocytes, and that angiotensin II activates monocytes and stimulates the 
expression of tissue factor as well as the release of pro-inflammatory cytokines (189), it is 
most likely that ACE in monocytes would aggravate inflammatory responses. To determine if 
the ACE signalling pathway exists in monocytes, we first examined ACE expression in 
monocytes derived from human blood. ACE expression significantly increased in monocytes 
cultured for 4 days with human serum and on exposure to ramiprilat we observed JNK 
activation. Taken together, these results indicate that there is ACE signalling in monocytes. 
On binding of ACE inhibitor, ACE functions as a signal transduction molecule in human 
monocytes.  
 
One of the most relevant findings from clinical trials related to either ACE inhibitors (190) or 
AT1 receptor antagonists (191;192)is their ability to delay the onset of type 2 diabetes. The 
mechanisms underlying this effect are unclear but may be related to the activation of PPARγ, 
a nuclear receptor that influences the expression of multiple genes involved in carbohydrate 
and lipid metabolism (40). Enalapril was shown to activate PPARγ in aortae from 
apolipoprotein E knockout mice (146) and also AT1 receptor blocker telmisartan acts as a 
selective PPARγ modulator (147;148). 
Human monocyte derived macrophages have been found to express PPARγ (193);198). 
PPARγ activation in monocytes and macrophages is associated with anti-inflammatory 
actions. PPARγ agonists were shown to inhibit monocyte cytokine production and 
macrophage activation (194;195). It has been reported that PPARγ activation leads to 
attenuation of early and advanced atherosclerosis (196).  
We next investigated the ability of ramiprilat to activate PPARγ in monocytes. Ramiprilat 
increased the PPARγ levels in the nuclear extracts of human monocytes but not in whole cell 
lysates. The increase in nuclear PPARγ levels by ramiprilat was similar to that of 
rosiglitazone which is a known PPARγ agonist and used to treat Type II diabetes. The  
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possible mechanism of the result observed, could be that ramiprilat might increase the PPARγ 
levels in the nucleus where it binds to its heterodimeric partner RXR and increases the gene 
expression. We next investigated whether this phenomenon could be reproduced in human 
endothelial cells, wherein ACE signalling pathway was demonstrated. We found that 
ramiprilat increased PPARγ levels in the nuclear extracts of human endothelial cells as well. 
This observation seems to be complex to understand as human umbilical vein endothelial 
cells generally have very low levels of PPARγ  and probably depends on the genetic make-up 
of the donor which may or may not be sensitive to treatment with ramiprilat and therefore the 
results observed were not so reproducible. We next sought to determine if ramiprilat has any 
effect on the promoter activity of PPAR’s as reported for telmisartan, an angiotensin II 
receptor blocker which increased the activity of PPRE. Endothelial cells expressing ACE and 
transfected with 3 copies of PPRE did not show any increase in activity on treatment with 
ramiprilat while rosiglitazone increased the PPRE activity and also PPARγ antagonist 
GW9662 along with rosiglitazone had a marginal effect. These results indicated the increase 
in PPARγ by ramiprilat is not through transcriptional activation but by indirect means which 
still needs further investigation. 
As we failed to see any promoter activation of PPRE by ramiprilat we next hypothesized that 
ramiprilat might increase the levels of 15-deoxy-D-12,14 prostaglandin J2 (15dPGJ2) which 
is a natural ligand for PPARγ by means of cyclooxygenase (COX) enzymes. Therefore we 
next determined COX-2 expression in monocytes treated with ramiprilat and we observed that 
ramiprilat was able to decrease the diminution of COX-2 levels upto 48 hours but the levels of 
15dPGJ2 were too low to be detected by ELISA. Taken together these results suggest that 
ACE inhibitors initiate ACE signalling and leads to enhanced expression of ACE, COX-2, 
CRBP-1 which in turn favours the heterodimerization of PPARγ with RXR. 
Angiotensin II has been shown to activate NF-κB mediated genes and thereby leading to the 
downregulation of PPAR’s (197). It has also been suggested that many of the anti-
inflammatory effects of PPAR’s may be due to the inhibition of the NF-κB signalling 
pathway (153). We therefore assessed whether ramiprilat downregulates NF-κB in human 
monocytes expressing ACE. Ramiprilat did not enhance DNA binding to  NF-κB in human 
monocytes compared to TNFα. Further investigation is needed to address this issue as to how 
ramiprilat interferes with NF-κB pathway.  
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4.4 ACE inhibitor regulates adiponectin, downstream target of PPARγ 
 
Since ramipril enhanced the plasma levels of CRBP1 in patients with type 2 diabetes or 
coronary artery disease and CRBP1 potentially influences the nuclear receptor proteins 
(RAR/RXR), which are abundant in adipose tissue and regulates adipocyte gene expression 
together with PPAR, we therefore analysed the effect of ACE inhibitor on adipokine 
expression as adipose tissue does have components of RAS. ACE inhibitors increased the 
adiponectin levels in the culture supernatant of adipocytes isolated from visceral fat. Plasma 
samples from mice (C57 black mice; ob/ob mice) treated with ramipril also demonstrated 
enhanced adiponectin levels compared to untreated control mice. 
 
Adiponectin levels are decreased in patients with obesity, diabetes and coronary artery 
disease. Treatment with ACE inhibitor restored the plasma adiponectin levels in patients with 
coronary artery disease. The mechanisms by which ramiprilat enhances adiponectin levels 
however is yet to be investigated. Taken together these data suggest that ACE inhibitor affects 
adipocyte homeostasis, probably through activation of RAR/RXR-PPARγ signalling. 
Enhanced plasma levels of anti-inflammatory and anti-atherogenic adipokine adiponectin may 
be the one of the ways by which ACE inhibitor exerts positive effects in patients with type 2 
diabetes and thereby preventing the onset of the disease. 
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Fig. 27: Scheme summarizing the effects of ACE inhibitor through ACE signalling. 
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Summary 
The angiotensin converting enzyme (ACE) is an important component of the renin-
angiotensin system (RAS) and is crucially involved in the homeostasis of fluid and electrolyte 
balance and thus in the regulation of blood pressure. The zinc metallopeptidase is involved in 
the generation of angiotensin II, a potent vasoconstrictor and in the degradation of bradykinin, 
a potent vasodilator. It is worth noting that ACE more readily hydrolyzes bradykinin than it 
does angiotensin I thus culminating in the net physiological effect of the production of a 
vasoconstrictor and the decrease in the availability of a vasodilator. ACE inhibitors have 
become one of the most successful therapeutic approaches as a first line of therapy in 
hypertension, and are also widely used in treating heart failure, myocardial infarction, stroke, 
coronary artery disease and impaired left ventricular function. However, one unexpected 
clinically relevant finding related to ACE inhibitors is their ability to delay the onset of type II 
diabetes that was revealed by various large clinical trials. However, the mechanisms 
underlying these beneficial effects of ACE inhibitor therapy are currently unclear and cannot 
be explained by the prevention of angiotensin II formation or the attenuated degradation of 
bradykinin. Thus the potential beneficial effects attributed to ACE inhibitors may occur 
independent of reductions in blood pressure paving way for new and/or unknown mechanism. 
Our group has recently redefined ACE as a signal transduction molecule which upon binding 
to ACE inhibitor turns on a signalling cascade leading to phosphorylation of Ser
1270 by CK2, 
activation of JNK and changes in gene expression in endothelial cells. However the 
mechanism by which ACE inhibitor initiates the signalling cascade was not clear. It was 
hypothesized that ACE, which is anchored to the membrane with a single transmembrane 
domain should dimerize prior to initiating further downstream signalling events in endothelial 
cells. Therefore, we sought to explore whether or not ACE forms dimers in endothelial cells 
and whether ACE dimerization is essential for the initiation of ACE signalling in endothelial 
cells. Using native gel electrophoresis, we found that ACE forms dimers in endothelial cells 
and that there is an increase in the dimer formation upon treatment of endothelial cells with 
ACE inhibitors. ACE homodimerization was also demonstrated using the split-ubiquitin 
system and chemical cross-linking experiments. ACE dimers are also formed in endothelial 
cells overexpressing the non-phosphorylatable ACE, wherein ACE signalling was abolished 
indicating that dimerization process is not influenced by the phosphorylation of the serine 
residue residing in the cytoplasmic tail. Monosaccharides like glucose, galactose and mannitol  
 Summary  63
did not have any influence on ACE-inhibitor induced dimerization. Making use of different 
monoclonal antibodies directed to the epitopes of N-domain which harbours carbohydrate 
recognizing domain, also did not affect dimerization. However, inactivation of the C-domain 
active site by introducing mutation of the key histidine residues in HEMGH consensus 
sequences, which complexes the zinc ions, abolished enzyme dimerization both in the basal 
state and in response to ramiprilat. Mutation of the C-domain also resulted in the loss of ACE 
inhibitor-induced ACE signalling, that is we failed to observe ramiprilat-induced increase in 
the phosphorylation of the Ser
1270 and the subsequent JNK activation. ACE-inhibitor induced 
dimerization precedes the phosphorylation of Ser
1270 and activation of JNK. Thus the ACE-
inhibitor induced dimerization via the C-domain of ACE represents the initial step in the ACE 
signalling pathway which involves the activation of JNK/c-Jun pathway and leading to the 
changes in the gene expression in endothelial cells.  
Our group previously identified ACE itself as well as cyclooxygenase-2 (COX-2) as two 
“ACE signalling-regulated” genes. To screen for additional genes regulated in a similar 
manner we used DNA microarray technology, to assess ramiprilat-induced changes in the 
endothelial cell gene expression. 21 genes were identified to be differentially regulated of 
which, 7 were upregulated and 14 were downregulated by ramiprilat. However, when 
screened at the protein level, we found no significant differences between the untreated 
control cells and those treated with ramiprilat. As several other cells and tissues possess a 
fully functional RAS we screened plasma samples from healthy volunteers as well as from 
patients with coronary artery disease for the proteins identified in the microarray. We 
observed that the cellular retinal binding protein-1 (CRBP-1) was detectable at low levels in 
plasma from patients and that ramipril markedly increased serum levels of this protein. 
Endothelial cells overexpressing CRBP-1 demonstrated increased RXRE and PPRE activity 
when stimulated with 9-cis retinoic acid and rosiglitazone respectively suggesting that CRBP-
1 might affect gene expression via heterodimerization of PPAR elements with RXR elements 
by virtue of its function as a transport protein of retinoic acid. Studies aimed at determining 
the consequences of elevated CRBP-1 expression on endothelial cell homeostasis are 
ongoing.   
Although the RAS has been described in many other tissues apart from endothelial cells, ACE 
signalling has not yet been addressed in tissues such as monocytes/macrophages, which have 
an increased ACE expression in an atherosclerotic setting. We observed that upon stimulation 
of cultured ACE expressing monocytes with ramiprilat, JNK is activated suggesting the  
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occurrence of ACE signalling in human monocytes. It is worth noting that ACE inhibitors 
delay the onset of type II diabetes in spite of moderate decrease in blood pressure. To further 
elucidate the mechanism underlying this effect, we found that ACE inhibitors increase the 
PPARγ levels in the nuclear extracts of ACE expressing monocytes which were also 
reproduced in human endothelial cells overexpressing human somatic ACE. However, 
ramiprilat did not have any direct effect on the activity of a luciferase-coupled promoter 
containing several copies of the PPRE in human endothelial cells. These results contrasted 
with the actions of the PPARγ agonist suggesting that ramiprilat enhances PPARγ levels 
through an indirect mechanism. We next hypothesized that ramiprilat might increase the 
levels of 15-deoxy-D12,14-prostaglandin J2 (15dPGJ2) which is a natural ligand for PPARγ 
via COX enzymes in monocytes. We observed that ramiprilat was able to decrease the 
diminution of COX-2 levels upto 48 hours of treatment but the levels of 15dPGJ2 were too 
low to be detected by ELISA. However ramiprilat enhanced the plasma levels of adiponectin, 
a downstream target of PPARγ, which is a anti-atherogenic and anti-inflammatory adipokine, 
in patients with coronary artery disease. Though adiponectin is a PPARγ-regulated gene, the 
observed increase in adiponectin might be attributed to the increase in RXR rather than via 
PPARγ.  
Taken together, the results of this investigation have revealed that ACE inhibitors initiate 
ACE signalling by eliciting the dimerization of the enzyme, more specifically via its C-
domain active centers. The ACE signalling cascade when activated leads to the enhanced 
expression of ACE, COX-2 and CRBP-1 which in turn favours the heterodimerization of 
PPARγ with RXR and thus results in the increased expression of “PPARγ regulated” genes 
such as adiponectin. The latter results provide a molecular basis for the observation that ACE 
inhibitors can delay the onset of type 2 diabetes in as much as it was possible to link ramipril 
with CRBP-1, RXR activity and the expression of adiponectin, an adipokine associated with 
improved insulin sensitivity. Further work is however required to elucidate the consequences 
of ACE inhibitors in monocytes and adipocytes as well as in intact animals. 
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6. Zusammenfassung 
 
Das Angiotensin-konvertierende Enzym (ACE) ist eine zentrale Komponente des Renin-
Angiotensin-Systems (RAS) und ist insbesondere für die Regulation des Wasser-Elektrolyt-
Haushaltes sowie für die Kontrolle des Blutdrucks von großer Bedeutung. Das Enzym 
wandelt zum einen Angiotensin I in das stark vasokonstrikitorisch wirkende Hormon 
Angiotensin II um und hydrolysiert zum anderen das vasodilatorisch wirkende Hormon 
Bradykinin in inaktive Fragmente. Die Hemmung des RAS durch ACE-Inhibitoren ist zu 
einer wichtigen, erfolgreichen therapeutischen Maßnahme geworden, nicht nur zur 
Behandlung des Bluthochdrucks, sondern auch bei Myokardinfarkten, Diabetes mellitus Typ 
II, Schlaganfällen, koronarer Herzkrankheit (KHK) sowie bei Links-Herz-Insuffizienz. 
Interessanterweise lässt sich eine Reihe der positiven Effekte der ACE-Inhibitoren nicht allein 
durch Senkung des Angiotensin II-Spiegels bzw. Anstieg der Bradykinin-Konzentration 
erklären. Vielmehr scheint es noch andere Wege zu geben, mittels derer ACE-Inhibitoren ihre 
positiven Wirkungen entfalten. 
Im Hinblick darauf ist von besonderem Interesse, dass das Enzym ACE erst kürzlich als 
Signaltransduktionsmolekül identifiziert werden konnte. Die Bindung von ACE-Inhibitoren 
an ACE löst in Endothelzellen eine Signaltransduktionskaskade aus, bei der zunächst die 
ubiquitäte Proteinkinase CK2 ACE an einem intrazellulären Serin-Rest (Ser
1270) 
phosphoryliert. Infolge dieser Phosphorylierung wird der c-Jun/JNK-Signalweg und der 
Transkriptionsfaktor AP-1 aktiviert, was zur Steigerung der Expression von ACE und 
Cyclooxygenase-2 (COX-2) führt. In Endothelzellen, die eine nicht-phosphorylierbare 
Mutante von ACE (S1270A) überexprimieren, findet das ACE-Signalling nicht statt. Da 
mittels der Technik inverser Micellen gezeigt werden konnte, dass ACE als Dimer vorliegen 
kann, sollte die physiologische Relevanz dieser Dimerisierung und deren Einfluß auf das 
ACE-Signalling in Endothelzellen untersucht werden. Mit Hilfe nativer Gelelektrophorese,  
sowie Experimenten mit dem Split-ubiquitin System oder chemischem „Cross-linking“ 
konnte im Rahmen dieser Doktorarbeit gezeigt werden, dass ACE in Endothelzellen als 
Dimer vorliegt und die Dimerisierung durch Gabe von ACE-Inhibitoren gesteigert wird. Da 
die nicht-phosphorylierbare, inaktive ACE-Mutante auch dimerisieren kann, konnte ein 
Einfluss der ACE-Phosphorylierung auf die Dimerisierung ausgeschlossen werden. Obwohl 
eine Dimerisierung des Enzyms über eine N-terminale Zucker-Seitenkette postuliert worden 
war, konnte im Rahmen dieser Arbeit die ACE-Inhibitor-induzierte Dimerisierung weder 
durch die Gabe von Monosacchariden wie Glukose, Galactose und Mannitol unterdrückt  
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werden, noch durch die Inkubation der Endothelzellen mit verschiedenen N-terminalen, 
monoklonalen ACE-Antikörpern. Die basale und ACE-Inhibitor-induzierte Dimerisierung 
von ACE konnte jedoch durch die Inaktivierung des C-terminalen, aktiven Zentrums von 
ACE durch Mutation der Histidinreste in der HEMGH-Konsensussequenz verhindert werden. 
Dies führte zur völligen Aufhebung des ACE-Signaltransduktion weges, d.h. weder die 
Ramiprilat-vermittelte Phosphorylierung an Ser
1270 noch die JNK-Aktivierung erfolgte. Somit 
konnte die durch ACE-Inhibitoren induzierte Dimerisierung über die carboxyterminale 
Domäne des Enzyms als Initiationspunkt der ACE-Signaltransduktion bestätigt werden.  
Mittels DNA-Microarray Technologie wurde ferner der Einfluss der ACE-Dimerisierung und 
der dadurch initiierten Signaltransduktion auf die Expression weiterer Gene untersucht, wobei 
21 durch Ramiprilat regulierte Gene identifiziert wurden. Sieben Gene wurden in ihrer 
Expression gesteigert, 14 abgeschwächt. Zahlreiche weitere Experimente zeigten jedoch, dass 
Ramiprilat keinen Einfluss auf die Menge der durch diese Gene kodierten Proteine in 
Endothelzellen hatte. Da eine Reihe anderer Zellen und Gewebe ein funktionelles RAS 
exprimieren, untersuchten wir auch das Blutplasma von gesunden Probanden und Patienten 
mit KHK. Interessanterweise fand sich im Plasma von Patienten unter Ramipril-Therapie eine 
erhöhte Konzentration des „Cellular retinol binding protein-1“ (CRBP-1), welches auch 
mittels Microarray als durch Ramiprilat-hochreguliertes Gen ermittelt worden war. In 
Endothelzellen führte eine Überexpression von CRBP-1 zu einem Anstieg der 
Promotoraktivität von RXRE und PPRE nach Stimulation durch 9-cis Retinolsäure und 
Rosiglitazon, was möglicherweise auf das erhöhte, zelluläre Angebot von Retinol-Produkten 
und einer daraus resultierenden vermehrten Dimerisierung von PPAR und RXR 
zurückzuführen ist.  
Obwohl das RAS nicht nur in Endothelzellen, sondern auch in anderen Geweben eine Rolle 
spielt, konnte das ACE-Signalling bislang noch nicht in anderen Geweben nachgewiesen 
werden. Insbesondere die Untersuchung des ACE-Signallings in Monozyten bzw. 
Makrophagen könnte von besonderem medizinischem Interesse sein, da in diesen Zelltypen 
die ACE-Expression im Rahmen der Entwicklung einer Atherosklerose deutlich ansteigt. Es 
scheint jedoch ein ACE-Signalling in Monozyten zu existieren, da Ramiprilat in diesen Zellen 
eine Aktivierung der JNK sowie eine Erhöhung der COX-2 Expression auslöst.  
Eine weiterer positiver Aspekt einer ACE-Inhibitor-Therapie ist, dass diese Medikamente die 
Ausbildung eines Diabetes mellitus Typ II verzögern. Experimente zur Ermittlung des 
zugrundeliegenden Mechanismus zeigten, dass die Behandlung von ACE-exprimierenden 
Monozyten oder Endothelzellen mit ACE-Inhibitoren zu einem erhöhten PPARγ-Level in den  
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Kernextrakten dieser Zellen führte. Allerdings scheint Ramiprilat die PPARγ-Expression nur 
indirekt zu beeinflussen, denn die PPRE-Promotoraktivität wurde durch die Behandlung von 
Endothelzellen mit Ramiprilat, im Gegensatz zu der Inkubation mit dem PPARγ-Agonisten 
Rosiglitazon, nicht beeinflusst. Eine Wechselwirkung zwischen ACE und PPARγ scheint in 
der Tat naheliegend, da Patienten mit KHK infolge einer Ramipril-Behandlung eine erhöhte 
Plasmakonzentration von Adiponectin aufweisen, das in seiner Expression durch PPARγ 
gesteigert wird und als Adipokin anti-inflammatorische und anti-atherogene Eigenschaften 
aufweist. 
  Zusammenfassend lässt sich sagen, dass das ACE-Inhibitor-vermittelte ACE-Signalling durch 
eine Dimerisierung des ACE initiiert wird und zum Anstieg der Expression von ACE, COX-2 
und CRBP-1 führt. Die gesteigerte CRBP-1-Bildung erhöht vermutlich die Bildung von 
PPAR/RXR-Heterodimeren, was in der vermehrten Expression von PPAR-regulierten Genen 
(z.B. Adiponectin) resultiert. 
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7. List of Abbreviations 
 
ACE        Angiotensin I converting enzyme  
ACE2     Angiotensin  converting  enzyme-2 
ATP     Adenosine  tri-phosphate 
BSA     Bovine  serum  albumin 
CK2     Casein  kinase  2 
DNA           Deoxy ribonucleic acid     
DTT     Dithiothreitol 
EDTA     Ethylene  diamine  tetraacetic  acid 
EGTA     Ethylene  glycol  tetraacetic  acid 
HEPES   4-(2-hydroxyethyl)-1-piperazineethanesulfonic  acid 
HUVEC    Human  umbilical  vein  endothelial  cells 
JNK     c-Jun  amino  terminal  kinase 
NMMHC      Non muscle myosin heavy chain  
PAEC     Porcine  aortic  endothelial  cells 
PBS     Phosphate  buffered  saline 
PMSF     Phenylmethylsulfonyl  fluoride 
TEMED    N,N,N',N'-Tetramethylethylenediamine 
TNFα     Tumor  necrosis  factor-α 
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